

MANUSCRIPT TEXT FILE

GWAS of Retinal Vessel Tortuosity Identifies 173 Novel Loci Revealing Genes and Pathways Associated with Vascular Pathomechanics and Cardiometabolic Diseases

Mattia Tomasoni, PhD^{1,2,7,†}; Michael Johannes Beyeler, MSc^{1,2,†}; Sofia Ortin Vela, MSc^{1,2,†}; Ninon Mounier, PhD^{2,3}; Eleonora Porcu, PhD^{2,3,4}; Tanguy Corre^{1,2,3}; Daniel Krefl, PhD^{1,2}; Alexander Luke Button, PhD^{1,2}; Hana Abouzeid, MD^{5,6}; Konstantinidis Lazaros, MD⁷; Murielle Bochud, MD, PhD³; Reinier Schlingemann, MD, PhD⁷; Ciara Bergin, PhD⁷; Sven Bergmann, PhD^{1,2,8}

¹Dept. of Computational Biology, University of Lausanne, Lausanne, Switzerland;

²Swiss Institute of Bioinformatics, Lausanne, Switzerland; ³Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland; ⁴Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland; ⁵Division of Ophthalmology, Geneva University Hospitals, Switzerland; ⁶Clinical Eye Research Center Memorial Adolphe de Rothschild, Geneva, Switzerland; ⁷Jules-Gonin Eye Hospital, Lausanne, Switzerland; ⁸Dept. of Integrative Biomedical Sciences, University of Cape Town, Cape Town, South Africa; [†]Authors contributed equally to this work.

Address for Correspondence:

Sven Bergmann, PhD
University of Lausanne
Genopode
1016 Lausanne
Switzerland
E-mail: sven.bergmann@unil.ch

Short Title: Tomasoni et al.; GWAS of Retinal Vessel Tortuosity

Count: 11 401 word

31 Abstract

32 **Background:** Fundus images allow for non-invasive assessment of the retinal vasculature whose
33 features provide important information on health. Blood vessel tortuosity is a morphological feature
34 associated with many diseases including hypertension.

35 **Methods:** We analyzed 116 639 fundus images of suitable quality from 63 662 participants from
36 three cohorts, namely the UK Biobank (n = 62 751), SKIPOGH (n = 397), and *OphthalmLaus* (n =
37 512). We used a fully automated image processing pipeline to annotate vessels and a deep
38 learning algorithm to determine the vessel type, characterizing these subjects in terms of their
39 median retinal vessel tortuosity specific to arteries and to veins. Tortuosity was measured by the
40 *distance factor* (the length of a vessel segment over its chord length), as well as measures that
41 integrate over vessel curvature. Using these measures as traits, we performed the largest genome-
42 wide association study (GWAS) of vessel tortuosity to date. We assessed gene set enrichment
43 using the novel high-precision statistical method *PascalX*.

44 **Results:** Higher tortuosity was significantly associated with higher incidence of angina, myocardial
45 infarction, stroke, deep vein thrombosis, and hypertension. We identified 175 significantly
46 associated genetic loci in the UK Biobank; 173 of these were novel and 4 replicated in our second,
47 much smaller, meta-cohort. We estimated heritability at ~25% using linkage disequilibrium score
48 regression. Vessel type specific GWAS revealed 114 loci for arteries and 63 for veins. Genes with
49 significant association signals included COL4A2, ACTN4, LGALS4, LGALS7, LGALS7B, TNS1,
50 MAP4K1, EIF3K, CAPN12, ECH1, and SYNPO2. These tortuosity genes were overexpressed in
51 arteries and heart muscle and linked to pathways related to the structural properties of the
52 vasculature. We demonstrated that tortuosity loci served pleiotropic functions as cardiometabolic
53 disease variants and risk factors. Concordantly, Mendelian randomization revealed causal effects
54 between tortuosity, BMI and LDL.

55 **Conclusions:** Several alleles associated with retinal vessel tortuosity point to a common genetic
56 architecture of this trait with cardiovascular diseases and metabolic syndrome. Our results shed
57 new light on the genetics of vascular diseases and their pathomechanisms and highlight how
58 GWASs and heritability can be used to improve phenotype extraction from high-dimensional data,
59 such as images.

60 **Keywords:** GWAS, retina, microvasculature, tortuosity, genomics, cardiometabolic disease,
61 Mendelian randomization

62 Nonstandard Abbreviations and Acronyms

63 BMI: body mass index	71 GO: gene ontology
64 BRB: blood-retina barrier	72 GWAS: genome-wide association study
65 CAD: coronary artery disease	73 LD: linkage disequilibrium
66 CVD: cardiovascular diseases	74 LDL: low-density lipoprotein
67 DBP: diastolic blood pressure	75 SBP: systolic blood pressure
68 DF: distance factor	76 SMC: smooth muscle cell
69 DVT: deep vein thrombosis	77 SNP: single nucleotide polymorphism
70 EC: endothelial cells	78 VEGF: vascular endothelial growth factor

79

80 **Clinical Perspective**

81 **What is new?**

- 82 • We automatically estimated arterial and venous tortuosity in over 100k retinal fundus images
- 83 using image analysis and deep learning.
- 84 • GWAS revealed 173 novel loci.
- 85 • Mendelian randomization showed that increased venous tortuosity reduces BMI whereas
- 86 elevated LDL levels reduce the tortuosity of both arteries and veins.
- 87 • Measuring tortuosity in terms of the *distance factor*, which is sensitive to total vessel
- 88 elongation, had higher heritability and more associated loci than other tortuosity measures
- 89 that are sensitive to local vessel bending.

90

91 **What are the clinical implications?**

- 92 • Tortuosity genes were overexpressed in the aorta, tibial artery, coronary artery, and in two
- 93 heart tissues.
- 94 • Higher tortuosity was associated with higher incidence of angina, myocardial infarction,
- 95 stroke, deep vein thrombosis and hypertension.
- 96 • We demonstrated a shared genetic architecture between retinal tortuosity and certain
- 97 diseases related to the vasculature, and the associations included several cardiometabolic
- 98 disease variants and risk factors. Further research is needed to investigate the potential of
- 99 the retinal vessel tortuosity as a clinically relevant biomarker for cardiovascular disease and
- 100 metabolic syndrome.
- 101 • Enriched pathways include a well-known therapeutic target for ocular diseases (VEGFA-
- 102 VEGFR2) affecting tissue remodeling. We highlight several transcription factors as
- 103 interesting targets for further experimentation.

104

105 INTRODUCTION

106 Cardiovascular diseases (CVD) are the leading cause of death in developed countries[1–3] and a
107 major societal health burden. Though several risk factors for CVD development, such as age,
108 smoking, and hypertension, have been firmly established, the degree of importance of vascular
109 properties as risk factors is unclear. Retinal fundus photos allow non-invasive in-vivo assessment of
110 the vascular system of the superficial inner retina, i.e. the central and branch veins and arteries plus
111 the venules and arterioles. These vessels are composed of tightly sealed endothelial cells (ECs),
112 forming the inner blood-retina barrier (BRB), encased by smooth muscle cells (SMCs) form to the
113 vessel wall [4,5]. Automatic segmentation of retinal vessels in fundus images is well established,
114 and is commonly used in standard clinical care to screen and diagnose ocular and systemic diseases
115 [6]. In diabetes, for example, hyperglycemia induces damage to the ECs and pericytes of the inner
116 BRB contributing to retinal edema and hemorrhage [7].

117 Pathological changes in the retinal vessels often coincide with those in the microvasculature of other
118 organs and may precede the progression of systemic vascular diseases. The retinal vasculature can
119 provide insights into neuro-degenerative diseases, such as Alzheimer’s, Parkinson’s, and vascular
120 dementia [8–12]. In addition, abnormalities in retinal parameters are of diagnostic value for systemic
121 diseases, including increased risk of diabetes [13–15], obesity [16] and CVD [17,18] (such as stroke
122 [19–22], coronary heart disease [23], peripheral artery disease [24], hypertension [21,25–33],
123 atherosclerosis [19,21,34], myocardial infarction [35,36], and nephropathies [37,38]).

124 In recent years, genome-wide association studies (GWAS) have been used to link genes with
125 phenotypes extracted from fundus images, such as vessel size [39,40], optic disc morphology
126 [41,42], vascular density [43], fractal dimensions [43] and vessel tortuosity [44]. The diameter of the
127 retinal microvasculature was associated with genes TEAD1, TSPAN10, GNB3 and OCA2 [39]. A
128 recently published study [43] on vascular density and fractal dimensions reported 7 and 13 single
129 nucleotide polymorphism (SNPs) associated with these traits respectively, including OCA2, MEF2C
130 and GNB3. Retinal vessel tortuosity has been associated with SNPs that map to the genes ACTN4
131 and COL4A2 [44] Tortuosity of the vasculature was reported in the context of CAD [45] and
132 connective tissue disease [46]. These results demonstrated that GWAS can reveal genes with a
133 potential role in modulating vascular properties and related pathomechanisms, though their power
134 has been often limited.

135 Here, we report the results of the largest GWAS on vessel tortuosity to date. Our study was motivated
136 by the clinical relevance of this trait to diseases [9,13,28,46–48], as significant associations were
137 already reported in smaller sample sizes, making further discoveries likely. We used images and
138 genotypes from 62 751 subjects in the UK Biobank and from 397 and 512 subjects of the much
139 smaller, yet independent, population-based cohorts SKIPOGH [49,50] and *OphthalmoLaus* [51]. We
140 constructed an automated image analysis pipeline to extract retinal tortuosity from these data as a
141 biomarker. We report the correlation with patient records, SNPs, genes, pathways, tissue
142 expression, pathomechanisms, and causal effects associated with this biomarker.

143 METHODS

144 Data: genotypes, phenotypes and fundus images

145 The UK Biobank is a population-based cohort of approximately 488 000 subjects with rich,
146 longitudinal phenotypic data and a median 10-year follow-up [52,53]. We analyzed 173 837 retinal
147 fundus images from 84 825 individuals. Genotyping was performed on Axiom arrays for a total of
148 805 426 markers, from which approximately 96 million genotypes were imputed. We used the subset
149 of 15 599 830 SNPs that had been assigned an rsID. We performed an additional quality control step
150 by filtering out SNPs with $MAF < 5 \times 10^{-4}$ (which translates to an expected minimum number of ~60

151 individuals expected to have at least one minor allele). Finally, we applied a filtering procedure [54]
152 to remove SNPs with imputation quality < 0.3. In addition to genomic information, we obtained
153 phenotypic information from the patient records: type-2 diabetes, angina, myocardial infarction, deep
154 vein thrombosis (DVT), stroke, hypertension and smoking status. Age, sex, and principal
155 components of genotypes were used to correct for biases in the genetic associations.

156 We performed replication via a meta-analysis of two independent, population-based cohorts: the
157 *Swiss Kidney Project on Genes in Hypertension* (SKIPOGH) [49,50] and *OphthalmLaus* [51].
158 SKIPOGH is a family-based, cross-sectional study exploring the role of genes and kidney
159 hemodynamics in blood pressure regulation and kidney function in the general population,
160 comprising 1 054 genotyped individuals. 1 352 retinal fundus images were available from 518
161 participants. The genotyping was performed with the Illumina Omni 2.5 chip. *OphthalmLaus* is a sub-
162 study of *Cohorte Lausannoise (CoLaus)*, a population-based cohort comprising 6 188 genotyped
163 individuals. 7 252 fundus images were available from 1 015 subjects. *CoLaus* has as its objective to
164 investigate the epidemiology and genetic determinants of CVD risk factors and metabolic syndrome:
165 participants were phenotyped accordingly. The genotyping was performed using the 500K Affymetrix
166 chip technology.

167 **Automated analysis of color fundus images and quality control**

168 We extended the software ARIA [55] to perform batch segmentation and positional annotation of
169 blood vessels, using the default parameters [56]. We applied a quality filter based on the total length
170 of the vasculature and on the number of vessels (see Supplemental Text 1). Roughly two out of
171 three images passed this strict quality control (116 639 out of 173 837 in the UK Biobank). Based on
172 ARIA's vessel annotations, we calculated a tortuosity measure known as the *distance factor* (DF)
173 [57], defined as:

$$174 \quad DF = \frac{s(C)}{\text{chord}(C)}$$

175 where the total vessel length, $s(C)$, is divided by the Euclidean distance between the vessel segment
176 endpoints, $\text{chord}(C)$. DF is referred to in a recent review as the arc over chord ratio [58]. In addition
177 to DF, we also calculated six other tortuosity phenotypes based on alternative measures using
178 integrals over the curvature along the vessel (see Supplemental Text 2).

179 We phenotyped each individual by calculating median retinal tortuosities, then averaging the values
180 derived from the left and right eye, when available (for the resulting distribution, refer to Supplemental
181 Text 3).

182 **Deep Learning classification of arteries and veins**

183 We calculated pixel-wise artery and vein classifications using the Deep Learning algorithm *Little W-*
184 *Net* [59]. For each vessel segment recognized by ARIA, we used the difference between pixels
185 classified as arterial and venous as a score that was required to be positive or negative for the
186 segment to be annotated as artery or vein, respectively. On a set of 44 images, manually annotated
187 by an ophthalmologist, we obtained an area under the curve of 0.93 and an accuracy of 0.88. Thus,
188 we performed vessel type classification for the entire set of retinal fundus images, computing artery-
189 and vein-specific tortuosity values (see Supplemental Text 4).

190 **Genome-wide association analyses**

191 We ran genetic association studies on tortuosity of arteries, of veins, and combining both vessel
192 types. We used BGENIE [60], applying linear regression to confounder-corrected, quantile-quantile
193 normalized, retinal vessel tortuosity on the genotypes of the matching subjects imputed to a panel
194 of approximately 15M genetic variants. In order to account for confounding effects [61], the following

195 variables were provided as covariates: age, sex, PC of the genotypes (we considered only PCs with
196 a significant correlation to tortuosity, namely 1, 2, 5, 6, 7, 8, 16, 17 and 18). We applied a Bonferroni
197 threshold of 5×10^{-8} . A list of independent SNP was obtained by performing linkage disequilibrium
198 (LD) pruning using the LDpair function of the R package LDlinkR [62]. Two SNPs were considered
199 independent if they had LD $r^2 < 0.1$ or were more than 500K bases apart (see [Supplemental Dataset](#)
200 [1](#)).

201 **Replication meta-cohort**

202 As the SKIPOGH cohort includes subjects with a high degree of relatedness, we used the EMMAX
203 function of the EPACTS software [63] and the kinship matrix in the model to account for family
204 structure. We also included the recruitment center as a covariable. For the GWAS on the
205 *OphthalmoLaus* cohort, we used the same parameters and tools as for the discovery cohort. Results
206 from SKIPOGH and *OphthalmoLaus* were meta-analyzed using an inverse-variance weighting
207 scheme for the respective effect sizes as well as a random-effects model (Supplemental Text 5).

208 To keep the multiple hypotheses testing burden low, we took a candidate gene approach.
209 Specifically, we used the Benjamini–Hochberg procedure [64], which applies no multiple hypothesis
210 testing correction for the top hits, and then corrects the association of the candidate locus of rank n
211 for n tests.

212 **Heritability estimates**

213 We used LD Score Regression [65] to estimate the SNP-based heritability of our tortuosity
214 measures.

215 **Novel method for gene-based tests**

216 We used *PascalX* [66], a novel high-precision pathway scoring algorithm that we developed building
217 on our *Pascal* [67] tool, to aggregate SNP-wise summary statistics into gene scores using a sum of
218 χ^2 statistics: *PascalX* takes into account LD by effectively transforming the sum of χ^2 from all SNPs
219 within the gene window into a new basis of independent “Eigen-SNPs” corresponding to a weighted
220 sum of χ^2 statistics. Using multiple-precision arithmetics, *PascalX* computes the corresponding null
221 cumulative probability distribution to essentially arbitrary precision, while other tools usually only
222 approximate the underlying distribution. We thus computed p-values up to a precision of 10^{-100} ,
223 allowing for accurate scoring of genes with contributions from extremely significant SNPs, which
224 become increasingly frequent in highly powered GWASs such as this one.

225 We used the following configurations: We computed gene scores from SNPs lying within a window
226 of 50kb before the transcription start site and 50kb after the transcript end. The annotation of the
227 gene positions was based on the Genome Reference Consortium Human genome build 37
228 (GRCh37/hg19) downloaded from the Ensembl biomart [68]; we considered only protein-coding and
229 lincRNA genes. The reference panel from the UK10K project [69] was used to estimate the SNP-
230 SNP correlations (LD effects). *PascalX* uncovered 265 significant genes (after Bonferroni correction
231 for 25 489 gene-based tests $p < 0.05 / 25489 \approx 2.0 \times 10^{-6}$).

232 **Gene set enrichment**

233 We used *PascalX* [66] to compute gene set enrichment scores based on ranking derived from the
234 gene-based tests. As a large number of genes have inflated p-values in highly powered GWASs,
235 this ranking approach was more conservative. We first computed scores for 2 868 canonical
236 pathways (BioCarta, KEGG, PID, Reactome, and WikiPathways), then extended our analysis to the
237 31 120 pathways in MSigDB (v7.2) [70]. To adjust for statistical dependence and co-expression,

238 genes that are less than 100kb apart were “fused” (i.e. considered as single entities termed “fusion
239 genes” [67]).

240 Tissue-wide gene expression analysis

241 We performed tissue-wide gene expression analysis using *PascalX* [66] on the whole GTEx [71] (v8)
242 dataset, comprising 54 tissues. We defined gene sets based on the significant genes from each of
243 our three GWAS on DF tortuosity (artery, vein and combined). *PascalX* was used to perform an
244 enrichment analysis that indicated whether these sets were over-expressed in any particular tissue.
245 *PascalX* corrected for the co-expression of gene sub-clusters within each gene set by merging
246 nearby genes to fusion genes. We computed the fusion genes expression values in transcripts per
247 kilobase million from the raw read counts. These values values were made uniform via ranking,
248 transformed to χ^2 -distributed random variables, summed, and tested against a χ^2 distribution with
249 as many degrees of freedom as there were “fusion genes” in each set. We applied a Bonferroni
250 threshold: $p = 0.05 / 54 = 9.2 \times 10^{-4}$.

251 Shared genetic architecture with disease

252 We computed the overlap between DF tortuosity SNPs (from the combined-vessel GWAS) and
253 disease-related SNPs. To this end, we first identified which of the independent SNPs in the
254 combined-vessel GWAS were listed in the GWAS Catalog [72]. We then extended this analysis by
255 considering DF tortuosity SNPs in LD ($r^2 > 0.8$) with disease-related SNPs in the GWAS Catalog.

256 Mendelian randomisation analysis

257 We performed two-sample bidirectional Mendelian randomisation [73,74] to search for evidence of
258 causal effects between DF tortuosity (from the combined-vessel GWAS) and the following traits:
259 body mass index (BMI), coronary artery disease (CAD), systolic blood pressure (SBP), and lipid
260 traits, namely high-density lipoprotein, low-density lipoprotein (LDL), total cholesterol, and
261 triglycerides. For each trait, we used independent ($r^2 < 0.01$) significant ($P < 5 \times 10^{-8}$) SNPs as
262 instrumental variables. All summary statistics (estimated univariate effect size and standard error)
263 originated from the most recent meta-analyses (not including UK Biobank individuals) and were
264 downloaded from the publicly available NIH Genome-wide Repository of Associations Between
265 SNPs and Phenotypes [75]. We only used SNPs on autosomal chromosomes available in the UK10K
266 reference panel [69], which allowed us to estimate the LD among these SNPs and prune them. We
267 removed strand ambiguous SNPs. Causal estimates were based on the inverse variance weighted
268 method [76] and calculated using the Mendelian randomisation R package [77].

269 Code Availability

270 Code for all computations is available on request to the corresponding author.

271 RESULTS

272 Baseline characteristics and tortuosity quantification

273 Following quality control measures, we analyzed 116 639 images from 62 751 subjects of the UK
274 Biobank (mean \pm SD age = 56 \pm 8 years; 35 098 females at birth [54%]; 4 618 smokers [7%]). We
275 analyzed 1 352 images from 379 subjects of the SKIPOGH cohort (mean \pm SD age = 48 \pm 16 years;
276 211 females [53%]; 107 smokers [27%]). We analyzed 7 254 images from 512 subjects of the
277 *OphthalmLaus* cohort (mean \pm SD age = 51 \pm 10 years; 270 females [53%]). Baseline characteristics
278 and disease prevalence are presented in Supplemental Text 6. For an overview of our pipeline see
279 Figure 1.

280 The distributions of DF tortuosity were similar across cohorts: long-tailed, left-skewed, with means
281 ranging from 1.030 (UK Biobank) to 1.034 (*OphthamoLaus*). DF was higher in the elderly population
282 (Cohen's $d = 0.49$, $p = 1 \times 10^{-195}$), while sex had limited impact (Cohen's $d = 0.049$, $p = 9 \times 10^{-10}$).
283 Overall, DF was higher in veins (Cohen's $d = 0.13$, $p = 9 \times 10^{-142}$). For details about the stratified
284 analysis of the DF phenotype in the UK Biobank see Supplemental Text 3.

285 We extracted six additional tortuosity measures based on alternative mathematical definitions.
286 Correlations analysis and dimensionality reduction in terms of principle components showed that the
287 DF is most similar to the path integral of the squared curvature (τ_3) and least similar to the path
288 integral of the curvature (τ_2). The other alternative measures (τ_{4-7}) were similar to each other, very
289 different from τ_2 and of intermediate similarity to the DF and τ_3 (see Supplemental Text 2).

290 **Vessel tortuosity correlates with disease status**

291 We found DF tortuosity (from the combined-vessel GWAS) to be associated with angina, myocardial
292 infarction, stroke, DVT and hypertension. Analyzing arteries and vein separately, we found that the
293 DF of arteries was significantly associated with hypertension ($beta = 0.19$, $p = 3 \times 10^{-56}$) and angina
294 ($beta = 0.09$, $p = 6 \times 10^{-4}$), but not with myocardial infarction, stroke or DVT. In the case of veins, the
295 DF was significantly associated with hypertension ($beta = 0.25$, $p = 7 \times 10^{-99}$), angina ($beta = 0.18$,
296 $p = 2 \times 10^{-10}$), myocardial infarction ($beta = 0.12$, $p = 2 \times 10^{-4}$), stroke ($beta = 0.16$, $p = 5 \times 10^{-5}$) and
297 DVT ($beta = 0.11$, $p = 5 \times 10^{-4}$). For predictive power over disease status, see Supplemental Text 7.

298 **Vessel tortuosity GWASs identify 173 novel loci**

299 We identified 7 072 significantly associated SNPs in the combined-vessel GWAS on DF tortuosity in
300 the UK Biobank ([Supplemental Dataset 4A](#)). The vessel type specific GWAS resulted in 6 563
301 significantly associated SNPs for arteries, and 2 896 SNPs for veins ([Supplemental Dataset 4B](#) and
302 [4C](#)). We applied LD pruning, identifying 128 independent loci in the combined-vessel GWAS, 116 in
303 the artery-specific GWAS, and 63 in the vein-specific GWAS. Accounting for overlap between these
304 sets (see Supplemental Text 9), we obtained a total of 175 independent lead SNPs (see Figure 2a-
305 c). The top 10 SNPs are listed in Table 1, ordered by significance (for complete listings, see
306 Supplemental File [1](#)). Among the significantly associated variants, rs1808382 and rs7991229 had
307 been previously reported [45] (Supplemental Text 8), whereas the remaining 173 independent lead
308 SNPs represented novel loci associated (see Supplemental File [5](#)).

309 **Heritability of DF is larger than for other tortuosity measures**

310 The SNP-based heritability differed substantially across tortuosity measures, with DF receiving the
311 highest estimate ($h^2_{\text{SNP}} = 0.25$, $SE = 0.025$). This was approximately twice the heritability estimate
312 of the six alternative curvature-based measures ($0.11 \leq h^2_{\text{SNP}} \leq 0.13$, $0.011 \leq SE \leq 0.012$,
313 Supplemental Text 2). We did not observe any significant genomic inflation (see Table 2). Heritability
314 also varied depending on vessel type ($h^2_{\text{SNP}} = 0.23$ [SE = 0.020] for arteries, and $h^2_{\text{SNP}} = 0.15$
315 [SE = 0.021] for veins). The distribution of the DF phenotype for each vessel type is shown in
316 Supplemental Text 3.

317 **Replication of lead SNPs and genes in a small meta-cohort**

318 We replicated four of the lead SNPs from the UK Biobank GWAS (see Figure 2e), and discovered
319 three associated genes (TNS1, AC011243.1, LHFPL2; see Figure 3e) [64]. Given the limited sample
320 size of the replication meta-cohort ($n = 911$), we performed additional analyses on trend of effect
321 sizes. We observed a Pearson correlation of $r = 0.53$ ($p = 1.2 \times 10^{-11}$) between the effect size
322 estimates in the two studies (see Figure 2d, Figure 3d and Supplemental Text 5).

323 **Tortuosity genes and pathways affect vascular tissue remodeling and angiogenesis**

324 Mapping the SNP-wise association signals onto genes (Methods) we identified 265 significant genes
325 in the discovery GWAS combining vessel types, 203 in the artery-specific GWAS, and 123 in the
326 vein-specific GWAS. Accounting for overlap between these sets (see Supplemental Text 9), we
327 obtained a total of 312 genes (see Figure 3a-c). Top genes are reported in Table 3 (for a complete
328 listing, see [Supplemental Dataset 6A / 6B / 6C](#)). A large fraction of these genes carried annotations
329 related to vessel integrity, vascular tissue remodeling and angiogenesis. Specifically, we identified a
330 cluster of highly significant genes on chromosome 19, including *ACTN4* (related to actin filament
331 bundling), *TNS1* (cross-linking of actin filaments), and *CAPN12* (involved in structural integrity to
332 blood vessel walls). This locus also included three genes involved in adhesion to the connective
333 tissue [78]: *LGALS7*, *LGALS7B* and *LGALS4*. We also replicated the highly significant association
334 of tortuosity with two type IV collagen genes, *COL4A2* and *COL4A1* [44]. *SYNPO2* (related to actin
335 polymerisation, vascular injury [79] and ocular growth [80], also received a highly significant
336 association. Finally, among the artery-specific genes, we found *FLT1* coding for VEGFR1, which
337 plays a role in vessel formation and vascular biology [81]. (See Discussion for further details and
338 interpretation of these results.)

339 Gene set enrichment (Methods) yielded 78 significant sets in total (see Figure 4), with the strongest
340 signals arising from the combined and artery-specific analysis (see Supplemental Text 9 and
341 [Supplemental Dataset 7A / 7B / 7C](#)). Similarly to genes, many of the pathways pointed to specific
342 biological processes, cellular components, and molecular functions related to vessel integrity and
343 remodeling. These included “human retinal fibroblasts”, “vascular smooth muscle cells” (both in the
344 kidney and the neuroepithelium), and “epithelium development”. We also observed a pathway
345 related to “vascular endothelial growth factors”, VEGFA-VEGFR2, which is a well-known therapeutic
346 target for ocular diseases. We highlight several transcription factors and binding motifs for further
347 experimentation (see Figure 4b). The role of integrity and development of blood vessels for tortuosity
348 was supported by the enrichment of several GO terms such as “circulatory system development”,
349 “anatomical structure morphogenesis” and “tube development”. The enriched terms “cell-substrate
350 junction”, “anchoring junction”, “actin” and “actomyosin” revealed some of the molecular players
351 involved. (See Discussion for more details).

352 Compared to the DF analysis, the alternative tortuosity measures had lower heritability and fewer
353 enriched genes and pathways. However, some were unique and disease-relevant, such as a
354 pathway related to “abnormal cardiac ventricle morphology” (see Supplemental Text 2).

355 **Tortuosity genes are overexpressed in arteries and heart tissues**

356 Performing enrichment analyses across expression data from 54 tissues, we found that tortuosity
357 genes were overexpressed in three types of arteries (i.e., aorta, tibial artery and coronary artery),
358 two heart tissues (i.e. ventricle and atrial appendage), and, less significantly, fibroblasts and
359 muscular tissues. The profile of enrichment significance values across tissues for tortuosity genes
360 detected by combined-vessel type GWAS analysis is more similar to that of the artery-specific GWAS
361 than that of vein-specific one (see Figure 5), which did not result in any significant tissue associations
362 (for a strict Bonferroni threshold of $p = 0.05/54 = 9.2 \times 10^{-4}$).

363 **Tortuosity loci are known disease variants**

364 Nine of the discovered tortuosity loci had been previously reported as disease variants that mapped
365 to specific genes (Table 4): four loci were linked to vascular diseases (coronary heart disease,
366 myocardial infarction, arterial hypertension, and diverticular disease), two loci were linked to ocular
367 diseases (glaucoma and myopia), and three loci were linked to other systemic diseases (chronic
368 lymphocytic leukemia, type 2 diabetes, and Alzheimer’s disease). Similarly, we identified 12 loci

369 influencing both tortuosity and disease risk factors. We also uncovered 26 additional disease variants
370 that have not been confidently mapped to a specific gene (see Supplemental Text 10).

371 **Genetic overlap with cardiometabolic risk factors**

372 We expanded our analysis of disease variants to SNPs belonging to the same LD block (Figure 6).
373 We observe a sizable number of tortuosity-associated variants that overlap with CVD (54 SNPs).
374 Several traits related to metabolic syndrome also stand out: blood pressure (55 SNPs for SBP, 49
375 for DBP, 15 for pulse pressure), blood cholesterol levels (54 SNPs), BMI (54 SNPs), blood pressure
376 linked to alcohol intake and smoking (44 SNPs for SBP + alcohol, 27 for DBP + alcohol) and type2
377 diabetes (5 SNPs). In addition, other CVD risk factors share a high number of variants associated
378 with tortuosity, such as protein levels (27 SNPs) and type1 diabetes (9 SNPs). Finally, we detected
379 an overlap with various eye morphology traits, including optic disc morphometry (40 SNPs).

380 **Causal effects between tortuosity, BMI and LDL**

381 Using inverse-variance weighting MR, we observed that exposure to elevated (standardized) levels
382 of LDL reduced the tortuosity of veins by 3% ($p = 0.02$) and arteries by 5% ($p = 0.001$). Conversely,
383 increased venous (but not arterial nor combined) tortuosity reduced BMI by 4.4% ($p = 0.01$) (see
384 Supplemental Text 11).

385 **DISCUSSION**

386 Blood vessel tortuosity is a complex trait whose variation is induced in part during developmental
387 angiogenesis and vascular differentiation and in part through vessel remodeling due to pathological
388 processes in adult life. Both sources of variation are modulated by the environment, but also
389 genetically through gene and regulatory variants that subtly modulate these processes. In order to
390 better understand the involved genetic architecture we conducted the largest GWAS on retinal vessel
391 tortuosity to date, identifying 173 novel loci and pinpointing genes and gene-sets enriched with these
392 primary association signals. Leveraging the unprecedented number of hits, we performed MR that
393 revealed the causal relationships between retinal tortuosity, BMI and blood lipids. This provides
394 context for the considerable overlap we observed between variants associated with vessel tortuosity
395 and cardiometabolic diseases as well as their risk factors. Our results were consistent with the
396 overexpression of tortuosity genes in the aorta, tibial artery, coronary artery, and heart tissues. We
397 found tortuosity genes to be involved in the development of blood vessels, the maintenance of vessel
398 integrity and the remodeling as a consequence of disease processes.

399 **Vessel integrity**

400 Several enriched GO categories that are integral to vessel development were enriched, namely
401 “morphogenesis of anatomical structures”, “development of circulatory system”, and “tube
402 development”. Similarly GO categories pertinent to the structural integrity of vessels and the stability
403 of specific tissues were highlighted: “cell-substrate junction” and “anchoring junction” which are
404 responsible for the mechanical attachment of a cell and its cytoskeleton to the extracellular matrix.
405 Molecularly, “actin cytoskeleton”, “actin binding”, “actin filament bundle organization”, and “positive
406 regulation of actin filament bundle assembly” highlighted the important role of actin.

407 Among the top hits, we found genes directly related to vessel integrity. The product of *ACTN4*,
408 contributes to cell adhesion and to assembly of the tight junction by mediating actin filament bundling.
409 The paralogues *COL4A1* and *COL4A2* provide structural support and elasticity to connective tissues
410 by forming the hetero-trimer $\alpha1\alpha1\alpha2$, which is the most abundant collagen in the basement
411 membrane [82]. We found both *COL4A2* and *ACTN4* to be over-expressed in vascular tissues (see
412 Supplemental Text 12). Two more genes with actin-related activity were also among our top hits:

413 *TNS1*, which promotes cell migration and regulates angiogenesis [83], and *SYNPO2*, which is
414 activated by actin polymerization, highly expressed in SMCs [79] and known to provide structural
415 integrity to blood vessel walls [84]. Finally, we identified three genes coding for galectins, which are
416 involved in adhesion to the connective tissue via modulation of cell-cell and cell-matrix
417 interactions [78]: *LGALS7*, its paralog *LGALS7B* and *LGALS4*.

418 **Vessel remodeling**

419 Pathological stresses such as inflammation, infection, or injury, can cause remodeling of vessels,
420 manifesting as occlusions, kinks, tubulations, or other collateral formation of vessels. Pathway
421 analysis identified gene sets of ECs (four sets), SMCs (2 sets), fibroblasts (1 set) and pericytes (1
422 set) which are the basic cell types composing vessel walls. Dysregulated response of vascular SMC
423 can induce hypertension, and excessive proliferation of these cells contributes to CVD progression
424 [85]. ECs dysfunction can lead to hyperpermeability, neurovascular decoupling and proinflammatory
425 responses [7]. We identified a gene set for “human retinal fibroblasts” consistent with the fact that
426 this cell type is the most common in connective tissue and involved in maintaining the extracellular
427 matrix. Under stress, fibroblasts proliferate resulting in the accumulation of extracellular materials
428 that ultimately limits elasticity [86]. In addition, we found enrichment in a gene set related to
429 “mesangial cells”, which are kidney-specific pericyte cells. Retinal capillaries are composed of
430 endothelial cells and pericytes. These contractile cells control blood flow in capillaries [87] and their
431 function is inhibited under stress, such as in high glucose conditions typical in diabetes [88].
432 Therefore dysregulation of these gene sets has the potential to induce vessel remodeling under
433 stress.

434 We identified genes directly involved in vessel remodeling. In particular, *FLT1* plays a role in the
435 process of collateral vessel formation, which is a form of vascular remodeling in response to stress,
436 such as hypoxia or hypertension [89]. *FLT1* is transcribed in several tissues including arteries and
437 heart [71] and translated into VEGFR1. VEGFR1 is upregulated in response to micro-inflammation
438 in the early stages of several vascular diseases [89]. In the retina, VEGFR1 is observed in ECs,
439 SMCs, pericytes and RPE cells (which modulate fibroblast proliferation), and excess VEGFR1
440 contributes to vessel leakage and angiogenesis [89].

441 **Associations with diseases**

442 We detected pleiotropic effects of tortuosity loci, which we showed to be independently associated
443 with CAD, myocardial infarction, hypertension, diabetes, chronic lymphocytic leukemia, Alzheimer’s
444 disease, myopia and glaucoma. We also found tortuosity genes to be involved in disease
445 pathomechanisms. *ACTN4*, our top hit, was recently associated with vasorelaxation [90], a
446 mechanism that can lead to hypertension when malfunctioning. The lead SNP in *ACTN4* tortuosity
447 (rs1808382) is also independently associated with CAD [45]. *COL4A1* mutation has been reported
448 as the cause of retinal arteriolar tortuosity [91] and cerebral small vessel disease [92] vessel leakage
449 and hyperpermeability [93]. Fittingly, *COL4A2* also figured among our variants with pleiotropic effects
450 on disease risk (see Table 4). Variants in the fetal genome near *FLT1* have been associated with
451 preeclampsia [94], a condition of pregnant women presenting with hypertension and damage to the
452 liver and kidneys, whose underlying mechanism involves abnormal formation of blood vessels in the
453 placenta [95]. Retinal vessel modifications have been observed to precede clinical onset of
454 preeclampsia and persist upto 12 months postpartum [96–98].

455 We elucidated causal links between tortuosity and disease risk factors by applying MR. Specifically,
456 we established that elevated LDL exposure causally reduces arterial tortuosity. High LDL is known
457 to cause the buildup of atherosclerotic plaque [99], which has been clinically linked to arterial
458 tortuosity [100,101]. In fact, arteriosclerosis may make retinal arterial walls less flexible and thereby
459 reduce their DF. We observed a *negative* causal effect of venous tortuosity on BMI, despite the

460 known *positive* correlation between BMI and retinal tortuosity [102], suggesting that environmental
461 factors may play a role in the relationship between BMI and vascular tortuosity.

462 **Limitations**

463 This study was subject to the following limitations. First, we focused on the DF as a tortuosity
464 measure, since the corresponding GWAS revealed many more significant loci, genes and pathways,
465 as well as a higher heritability estimate in comparison to the alternative curvature-based tortuosity
466 measures. These measures are more sensitive to local physiological vessel features, such as
467 aneurysms or sharp bending (“kinks”), while DF only captures the total vessel elongation.
468 Interestingly, the GWAS for these measures revealed several specific genes and pathways that were
469 not significant in the DF analysis, which may be associated with pathologies manifesting as local
470 disruptions in the microvascular network. Further work is needed to elucidate to what extent the
471 stronger association signals for the DF are due to its robustness as a tortuosity measure or its quality
472 to capture *total* vessel elongation as the most physiologically relevant trait. Second, due to the small
473 size of our replication meta-cohort we only had enough power to replicate 4 of our 173 hits.
474 Nevertheless, the effect sizes of SNPs and genes in the replication studies correlated strongly with
475 those in the discovery cohort, providing independent evidence that they were not driven by any
476 artifacts specific to the UK Biobank [52]. Moreover, our gene and pathway analyses indicate that
477 these signals make biological sense. Finally, we did not adjust for spherical equivalent refractive
478 error, which may have confounded our measurements to some degree. Investigating the impact of
479 this and other corrections on the heritability estimates could shed more light on their usefulness.

480 **Conclusion**

481 This study exploits advanced automated image processing and deep learning to characterize
482 different *vessel type specific* retinal tortuosity measures from >100k fundus images to conduct a
483 high-powered GWAS on this trait. The resulting significant association signals for 175 genetic loci
484 allowed us to estimate the heritability of tortuosity, identify genes, annotated gene-sets and tissues
485 relevant for this trait, and reveal pleiotropic links with and causal effects to or from disease-related
486 traits. This range of analyses was largely possible due to the large data set made available by the
487 UK Biobank, in terms of both genetic analysis and the high-dimensional data available from fundus
488 images. Combining these data provided novel insights into the genetic architecture of retinal
489 tortuosity, the associated morphological features, the potential disease processes, and the
490 identification of candidate targets for ocular and systemic treatments.

491 **ACKNOWLEDGEMENTS**

492 This work was conducted using the UK Biobank (application ID 43805) and SKIPOGH. Thanks to
493 Micha Hersch for inspiring this project, to the UK Biobank team for their support and responsiveness,
494 and to all UK Biobank participants for sharing their personal data. We also thank aSciStance Ltd for
495 their help in revising the manuscript.

496 **SOURCE OF FUNDING**

497 This work was supported by the Swiss National Science Foundation (#FN 310030_152724/1 to SB)
498 and by the Swiss Personalized Health Network (2018DRI13 to Thomas J. Wolfensberger). The
499 SKIPOGH study was also supported by the Swiss National Science Foundation (#FN 33CM30-
500 124087 to MB). The *OphthalmoLaus* study was supported by the Claire et Selma Kattenburg
501 Foundation.

502 **DISCLOSURES**

503 The authors declare no competing interests.

504 **AUTHOR CONTRIBUTIONS**

505 MT and SB designed the study. MT and MJB performed QC on the raw images. MT and SOV
506 extracted tortuosity measurements from the image data (UK Biobank, *OphthalmosLaus* and
507 SKIPOGH). MJB performed classification of arteries and veins. MT carried out the median DF
508 tortuosity GWAS, with the guidance of SB, NM and EP. SOV carried out the tortuosity GWASs based
509 on alternative measures with input from MT. MJB and SOV carried out gene and pathway scoring
510 with the guidance of DK. ALB performed LD Score Regression analysis. SOV evaluated the
511 correlation between different tortuosity measures and their impact on genetic associations. MT and
512 TC performed the replication analysis in SKIPOGH with input from MB. HA, LK, RS and CB provided
513 ophthalmological expertise and manually annotated the raw image data. MT, CB and SB lead the
514 writing of the manuscript with contributions from all other authors.

515 **SUPPLEMENTAL**

516 Supplemental Methods (Supplemental Text 1–5)
517 Supplemental Results (Supplemental Text 6–13)
518 Supplemental Datasets 1–3, 4A–C, 5, 6A–C, 7A–C

TABLES

Chr	SNP	EA	RA	freq	beta	$-\log_{10} p$	GWAS type
13	rs9559797	G	C	0.580	-0.162	182.4	artery and vein
19	rs16972767	G	A	0.473	-0.150	164.6	artery and vein
4	rs17008193	T	C	0.403	-0.089	55.0	artery and vein
7	rs187691758	A	G	0.005	0.627	53.2	vein
4	rs12506823	G	A	0.406	0.083	47.9	artery and vein
2	rs2571461	T	G	0.601	-0.082	47.1	artery and vein
15	rs12913832	A	G	0.744	0.080	43.6	artery and vein
12	rs11045245	A	G	0.375	0.073	37.3	artery
5	rs784420	A	G	0.281	0.078	37.0	artery and vein
4	rs11727963	G	A	0.166	0.092	35.1	artery

520 **Table 1 | Top retinal tortuosity SNPs.** The 10 most significant DF tortuosity SNPs, ordered by p-
 521 value. For full results, refer to the list of 175 independent lead SNPs in [Supplemental Dataset 1](#).
 522 **Chr:** chromosome; **SNP:** rsIDs of the single nucleotide polymorphism; **EA:** effect allele; **RA:**
 523 reference allele; **freq:** allele frequency of effect allele; **beta:** effect size estimate; **$-\log_{10} p$:**
 524 normalized p-value in the discovery cohort; **GWAS type:** vessel type to which the signal applied.

GWAS type	h^2_{SNP}	lambda GC	mean Chi2	intercept	ratio
combined-vessel	0.25 (0.025)	1.14	1.31	1.01 (0.01)	0.03 (0.03)
artery	0.23 (0.020)	1.12	1.27	1.00 (0.01)	< 0
vein	0.15 (0.021)	1.10	1.18	1.00 (0.01)	< 0

525 **Table 2 | SNP-based heritability.** h^2_{SNP} : portion of phenotypic variance cumulatively explained by
 526 the SNPs; **lambda GC:** inflation, measure of the effect of confounding and polygenicity acting on
 527 the trait; **intercept:** LD score regression intercept (values close to 1 indicates little influence of
 528 confounders, mostly of population stratification); **ratio:** ratio of the proportion of the inflation in the
 529 **mean Chi²** that is not due to polygenicity (a ratio close to, or smaller than, 0 is desirable as it
 530 indicates low inflation from population stratification). SE are given in parentheses.

Gene	Chr	base pair	$-\log_{10} p$ combined	$-\log_{10} p$ artery	$-\log_{10} p$ vein
ACTN4	19	39,138,289	> 100	> 100	> 100
CAPN12	19	39,220,827	> 100	> 100	> 100
EIF3K	19	39,109,735	> 100	> 100	> 100
LGALS7	19	39,261,611	> 100	> 100	> 100
LGALS7B	19	39,279,851	> 100	> 100	> 100
COL4A2	13	110,958,159	> 100	> 100	9.5
LGALS4	19	39,292,311	> 100	34.5	> 100
MAP4K1	19	39,078,281	> 100	34.3	> 100
TNS1	2	218,664,512	> 100	32.7	16.9

ECH1	19	39,306,062	> 100	15.3	> 100
AC104534.3	19	39,310,806	> 100	14.0	> 100


531 **Table 3 | Top retinal tortuosity genes.** The 15 most significant DF tortuosity genes, for each
 532 GWAS (combining all vessels, considering only arteries, and only veins). P-values were computed
 533 by *PascalX* [66] (precision cutoff: 1×10^{-100}). For full results, refer to [Supplemental Dataset 6A](#) / [6B](#) /
 534 [6C](#).

Shared SNP	Disease GWAS	Gene	$-\log_{10} p$	ref
rs875107	diverticular disease	ANO1	22.5	[105]
rs7588567	glaucoma	NCKAP5	21.2	[106]
rs7119	type 2 diabetes	HMG20A	17.5	[107]
rs936226	hypertension	CYP1A2	14.7	[108]
rs757978	chronic lymphocytic leukemia (CLL)	FARP2	10.4	[109]
rs2753462	myopia	FARP2	10.4	[110]
rs6725887 (*)	coronary heart disease	WDR12	9.6	[111]
rs6725887 (*)	myocardial infarction	WDR12	9.6	[112]
rs9381040	Alzheimer's disease	TREML2	6.0	[113]
rs11083475	heart rate (rhythm disorders)	ACTN4	> 100	[114]
rs9555695	waist-hip ratio (obesity)	COL4A2	> 100	[115]
rs2571445	lung function (pulmonary disease)	TNS1	> 100	[116]
rs3791979	intraocular pressure (open angle glaucoma)	TNS1	> 100	[117]
rs17263971	eGFR (Chronic Kidney Disease) and retinal dysfunction	SYNPO2	28.7	[79,118]
rs35252676	pulse pressure (CVD)	LHFPL2	26.6	[119]
rs1378942 (*)	diastolic blood pressure (CVD)	CSK	23.4	[120]
rs1378942 (*)	mean arterial pressure (CVD)	CSK	23.4	[121]
rs17355629	pulse pressure (CVD)	LRCH1	19.6	[122]
rs7655064	waist-hip ratio (obesity)	MYOZ2	14.5	[115]
rs6495122	diastolic blood pressure (CVD)	CPLX3	14.5	[123]
rs12913832	intraocular pressure (open angle glaucoma)	HERC2	12.3	[124]
rs9303401	cognitive ability (mental disorders)	PPM1E	10.01	[125]

535 **Table 4 | Pleiotropic disease-variants.** List of variants identified in the tortuosity GWAS
 536 (combined-vessel analysis) which were found to be associated with a disease outcome or risk
 537 factor in an independent study. We report only exact variants (same rsID in both tortuosity and
 538 disease GWAS), which we could confidently map to a gene. Gene p-values were computed by
 539 *PascalX* [66]. Variants associated with more than one disease are marked by a star (*)


540

FIGURES




541

542 **Figure 1 | Pipeline and results.** Relevant phenotypes, genotypes and fundus images were
 543 collected from the UK Biobank, *OphtalmoLaus* and SKIPOGH. After quality control, the images
 544 were processed by deep learning, classifying arteries and veins. A range of tortuosity measures
 545 were then calculated, which provided the phenotypes for the GWASs. The primary results were
 546 173 novel genetic trait loci. The association signals pointed to a shared genetic architecture of
 547 retinal tortuosity and disease (metabolic syndrome and CVD). Their aggregation on annotated
 548 gene-sets identified relevant pathways and GO terms. Tissue-wide expression analysis revealed
 549 expression in the arteries and heart. Correlation analysis revealed associations between retinal
 550 tortuosity and cardiometabolic diseases.



551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569


Figure 2 | SNP p-values and effects. **a**, Manhattan plot of Genome-Wide Association Study (GWAS) of retinal vessel tortuosity, combining all vessel types (both arteries and veins). The red line indicates the genome-wide significance level after Bonferroni correction ($p = 5 \times 10^{-8}$). Oblique dashes on top of peaks mark extremely significant p-values that have been cropped. Squares mark the position of disease SNPs (see Table 4). The trait was corrected for phenotypic variables which showed a statistically significant association, i.e.: age, sex, and a subset of principal components of genotypes. **b**, Manhattan plots of the vessels-specific GWAS (artery-specific on top, vein-specific at the bottom). Confounder correction, significance level and cropping of extremely significant p-values as in the (a). **c**, GWAS q-q plot: arteries in red, veins in blue, combined-vessels signal in black; the genome-wide significance level is represented as a green dashed line. **d**, Statistically significant correlation between the measured effect sizes in the discovery cohort (UK Biobank, $n = 62\,751$) and replication meta-cohort (SKIPOGH plus *OphthmoLaus*, $n = 911$). We considered all lead (independent) SNPs in the UK Biobank. We could find 136 with matching rsIDs in the replication meta-cohort, 90 of which had the same sign of their effect size estimate in the UK Biobank. The resulting Pearson correlation is $r = 0.53$; $t = 7.28$, $p = 1.18 \times 10^{-11}$. **e**, Benjamini-Hochberg procedure on discovery lead SNPs from the UK Biobank yields 4 hits in the replication cohort.



570

571

572 **Figure 3 | Gene p-values and replication scores.** **a**, Gene-based Manhattan plot of retinal vessel
 573 tortuosity, combining all vessel types (both arteries and veins). Gene-based tests were computed
 574 by *PascalX* [66]. The red line indicates the genome-wide significance level after Bonferroni
 575 correction ($p = 5 \times 10^{-8}$). Squares mark the position of particularly relevant genes (see
 576 corresponding Results section). **b**, Gene-based Manhattan plots of the vessels-specific GWAS
 577 (artery-specific on top, vein-specific at the bottom). **c**, q-q plot of gene p-values: arteries in red,
 578 veins in blue, combined-vessel signal in black; the genome-wide significance level is represented
 579 as a green dashed line. **d**, Statistically significant correlation between q-q normalized genes' p-
 580 values in the discovery (UK Biobank) and in the replication meta-cohort (SKIPOGH +
 581 *OphthmoLaus*). Only genes that were significant in the discovery cohort were considered. The
 582 resulting Pearson correlation is $r = 0.13$; $p = 0.02$. **e**, Benjamini-Hochberg generates 3 hits in the
 583 replication meta-cohort. Only genes that were significant in the discovery cohort were considered.



584

585

586

587

588

589

590


591

592

593


594

Figure 4 | Enriched pathways and gene-sets. Arteries in red, veins in blue, combined-vessel signal in black: scores for 31 120 gene-sets in MSigDB (v7.2) [103] were calculated by *PascalX* [66]. Only gene-sets for which significance was reached by at least one GWAS are shown. The red dashed line indicates Bonferroni-threshold ($-\log_{10} p = 5.7$). The number of genes in each set is indicated in squared brackets. Gene-set names have been shortened and some redundant GO categories are not shown. For details, refer to the extended plot in Supplemental Text 13. **a**, Enrichment in GO categories. **b**, Enrichment in pathways referring to a particular molecule (typically a transcription factor) and/or binding motif. **c**, Enrichment in gene-set obtained from transcriptomic analysis of tissues of treated cell types.



595

596 **Figure 5 | Tissue expression results.** Arteries in red, veins in blue, combined-vessel signal in
 597 black: tissue-specific gene expression analysis of GTEx (v8) [71] performed using *PascalX* [66].
 598 We defined sets based on the significant genes from each of the three GWAS we carried out and
 599 asked whether they were over-expressed in a particular tissue.



600

601 **Figure 6 | Overlap in genetic signals with diseases and other complex traits.** Arteries in red,
 602 veins in blue, combined-vessel signal in black: number of variants shared with other traits reported
 603 in the GWAS Catalog [72] (also considering SNPs in high LD with the lead SNP, $r^2 > 0.8$). Only
 604 traits with at least 5 shared associations are included (for a full list, including rsIDs, refer to the
 605 [Supplemental Dataset 3](#)). The traits with the highest number of shared SNPs belong to metabolic
 606 syndrome (blood pressure, BMI, blood cholesterol levels) and CVD. This analysis was generated
 607 using FUMA [104].

REFERENCES

1. Wilkins E, Wilson L, Wickramasinghe K, Bhatnagar P, Leal J, Luengo-Fernandez R, et al. European cardiovascular disease statistics 2017. 2017 [cited 25 May 2021]. Available: <https://researchportal.bath.ac.uk/en/publications/european-cardiovascular-disease-statistics-2017>
2. Federal Statistical Office. Cause of death statistics. Bundesamt für Statistik (BFS); 2021.
3. Rana JS, Khan SS, Lloyd-Jones DM, Sidney S. Changes in Mortality in Top 10 Causes of Death from 2011 to 2018. *J Gen Intern Med.* 2021;36: 2517–2518.
4. Díaz-Coránguez M, Ramos C, Antonetti DA. The inner blood-retinal barrier: Cellular basis and development. *Vision Res.* 2017;139: 123–137.
5. Klaassen I, Van Noorden CJF, Schlingemann RO. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. *Prog Retin Eye Res.* 2013;34: 19–48.
6. Liew G, Wang JJ, Mitchell P, Wong TY. Retinal vascular imaging: a new tool in microvascular disease research. *Circ Cardiovasc Imaging.* 2008;1: 156–161.
7. Duh EJ, Sun JK, Stitt AW. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. *JCI Insight.* 2017;2. doi:10.1172/jci.insight.93751
8. MacCormick IJC, Czanner G, Faragher B. Developing retinal biomarkers of neurological disease: an analytical perspective. *Biomark Med.* 2015;9: 691–701.
9. Patton N, Aslam T, Macgillivray T, Pattie A, Deary IJ, Dhillon B. Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: a rationale based on homology between cerebral and retinal microvasculatures. *J Anat.* 2005;206: 319–348.
10. Liao H, Zhu Z, Peng Y. Potential Utility of Retinal Imaging for Alzheimer’s Disease: A Review. *Front Aging Neurosci.* 2018;10: 188.
11. Dumitrascu OM, Qureshi TA. Retinal Vascular Imaging in Vascular Cognitive Impairment: Current and Future Perspectives. *J Exp Neurosci.* 2018;12: 1179069518801291.
12. Baker ML, Hand PJ, Wang JJ, Wong TY. Retinal signs and stroke: revisiting the link between the eye and brain. *Stroke.* 2008;39: 1371–1379.
13. Weiler DL, Engelke CB, Moore ALO, Harrison WW. Arteriole tortuosity associated with diabetic retinopathy and cholesterol. *Optom Vis Sci.* 2015;92: 384–391.
14. Gulshan V, Peng L, Coram M, Stumpe MC, Wu D, Narayanaswamy A, et al. Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs. *JAMA.* 2016;316: 2402–2410.
15. Mookiah MRK, Acharya UR, Fujita H, Tan JH, Chua CK, Bhandary SV, et al. Application of different imaging modalities for diagnosis of Diabetic Macular Edema: A review. *Comput Biol Med.* 2015;66: 295–315.
16. Wang JJ, Taylor B, Wong TY, Chua B, Rochtchina E, Klein R, et al. Retinal vessel diameters and obesity: a population-based study in older persons. *Obesity.* 2006;14: 206–214.
17. Poplin R, Varadarajan AV, Blumer K, Liu Y, McConnell MV, Corrado GS, et al. Prediction of cardiovascular risk factors from retinal fundus photographs via deep learning. *Nat Biomed Eng.* 2018;2: 158–164.
18. Flammer J, Konieczka K, Bruno RM, Virdis A, Flammer AJ, Taddei S. The eye and the heart. *Eur Heart J.* 2013;34: 1270–1278.
19. Seidelmann SB, Claggett B, Bravo PE, Gupta A, Farhad H, Klein BE, et al. Retinal Vessel Calibers in Predicting Long-Term Cardiovascular Outcomes: The Atherosclerosis Risk in Communities Study. *Circulation.* 2016;134: 1328–1338.
20. Ikram MK, Ong YT, Cheung CY, Wong TY. Retinal vascular caliber measurements: clinical significance, current knowledge and future perspectives. *Ophthalmologica.* 2013;229: 125–136.
21. Kawasaki R, Cheung N, Wang JJ, Klein R, Klein BE, Cotch MF, et al. Retinal vessel diameters and risk of hypertension: the Multiethnic Study of Atherosclerosis. *J Hypertens.* 2009;27: 2386–2393.
22. Ikram MK, de Jong FJ, Bos MJ, Vingerling JR, Hofman A, Koudstaal PJ, et al. Retinal vessel diameters and risk of stroke: the Rotterdam Study. *Neurology.* 2006;66: 1339–1343.
23. Liew G, Mitchell P, Rochtchina E, Wong TY, Hsu W, Lee ML, et al. Fractal analysis of retinal microvasculature and coronary heart disease mortality. *Eur Heart J.* 2011;32: 422–429.

24. Wintergerst MWM, Falahat P, Holz FG, Schaefer C, Schahab N, Finger R. Retinal Vasculature assessed by OCTA in Peripheral Arterial Disease. *Invest Ophthalmol Vis Sci.* 2020;61: 3203–3203.
25. Konstantinidis L, Guex-Crosier Y. Hypertension and the eye. *Curr Opin Ophthalmol.* 2016;27: 514–521.
26. Smith W, Wang JJ, Wong TY, Rochtchina E, Klein R, Leeder SR, et al. Retinal arteriolar narrowing is associated with 5-year incident severe hypertension: the Blue Mountains Eye Study. *Hypertension.* 2004;44: 442–447.
27. Wong T, Mitchell P. The eye in hypertension. *Lancet.* 2007;369: 425–435.
28. Cheung CY-L, Zheng Y, Hsu W, Lee ML, Lau QP, Mitchell P, et al. Retinal vascular tortuosity, blood pressure, and cardiovascular risk factors. *Ophthalmology.* 2011;118: 812–818.
29. Wong TY, Shankar A, Klein R, Klein BEK, Hubbard LD. Prospective cohort study of retinal vessel diameters and risk of hypertension. *BMJ.* 2004;329: 79.
30. Dimmitt SB, West JN, Eames SM, Gibson JM, Gosling P, Littler WA. Usefulness of ophthalmoscopy in mild to moderate hypertension. *Lancet.* 1989;1: 1103–1106.
31. Leung H, Wang JJ, Rochtchina E, Wong TY, Klein R, Mitchell P. Impact of current and past blood pressure on retinal arteriolar diameter in an older population. *J Hypertens.* 2004;22: 1543–1549.
32. Wong TY, Klein R, Sharrett AR, Duncan BB, Couper DJ, Klein BEK, et al. Retinal arteriolar diameter and risk for hypertension. *Ann Intern Med.* 2004;140: 248–255.
33. Ikram MK, Witteman JCM, Vingerling JR, Breteler MMB, Hofman A, de Jong PTVM. Retinal vessel diameters and risk of hypertension: the Rotterdam Study. *Hypertension.* 2006;47: 189–194.
34. Sharrett AR, Hubbard LD, Cooper LS, Sorlie PD, Brothers RJ, Nieto FJ, et al. Retinal arteriolar diameters and elevated blood pressure: the Atherosclerosis Risk in Communities Study. *Am J Epidemiol.* 1999;150: 263–270.
35. Woo SCY, Lip GYH, Lip PL. Associations of retinal artery occlusion and retinal vein occlusion to mortality, stroke, and myocardial infarction: a systematic review. *Eye.* 2016;30: 1031–1038.
36. Rim TH, Han JS, Oh J, Kim DW, Kang S-M, Chung EJ. Retinal vein occlusion and the risk of acute myocardial infarction development: a 12-year nationwide cohort study. *Sci Rep.* 2016;6: 22351.
37. Sabanayagam C, Xu D, Ting DSW, Nusinovici S, Banu R, Hamzah H, et al. A deep learning algorithm to detect chronic kidney disease from retinal photographs in community-based populations. *The Lancet Digital Health.* 2020;2: e295–e302.
38. Park HC, Lee Y-K, Cho A, Han CH, Noh J-W, Shin YJ, et al. Diabetic retinopathy is a prognostic factor for progression of chronic kidney disease in the patients with type 2 diabetes mellitus. *PLoS One.* 2019;14: e0220506.
39. Jensen RA, Sim X, Smith AV, Li X, Jakobsdóttir J, Cheng C-Y, et al. Novel Genetic Loci Associated With Retinal Microvascular Diameter. *Circ Cardiovasc Genet.* 2016;9: 45–54.
40. Ikram MK, Sim X, Jensen RA, Cotch MF, Hewitt AW, Ikram MA, et al. Four novel Loci (19q13, 6q24, 12q24, and 5q14) influence the microcirculation in vivo. *PLoS Genet.* 2010;6: e1001184.
41. Springelkamp H, Mishra A, Hysi PG, Gharahkhani P, Höhn R, Khor C-C, et al. Meta-analysis of Genome-Wide Association Studies Identifies Novel Loci Associated With Optic Disc Morphology. *Genet Epidemiol.* 2015;39: 207–216.
42. Han X, Qassim A, An J, Marshall H, Zhou T, Ong J-S, et al. Genome-wide association analysis of 95 549 individuals identifies novel loci and genes influencing optic disc morphology. *Hum Mol Genet.* 2019;28: 3680–3690.
43. Zekavat SM, Raghu VK, Trinder M, Ye Y, Koyama S, Honigberg MC, et al. Deep Learning of the Retina Enables Phenome- and Genome-wide Analyses of the Microvasculature. *Circulation.* 2021. doi:10.1161/CIRCULATIONAHA.121.057709
44. Veluchamy A, Ballerini L, Vitart V, Schraut KE, Kirin M, Campbell H, et al. Novel Genetic Locus Influencing Retinal Venular Tortuosity Is Also Associated With Risk of Coronary Artery Disease. *Arterioscler Thromb Vasc Biol.* 2019;39: 2542–2552.
45. Veluchamy A, Ballerini L, Vitart V, Schraut KE, Kirin M, Campbell H, et al. Novel Genetic Locus Influencing Retinal Venular Tortuosity Is Also Associated With Risk of Coronary Artery Disease. *Arterioscler Thromb Vasc Biol.* 2019;39: 2542–2552.
46. Welby JP, Kim ST, Carr CM, Lehman VT, Rydberg CH, Wald JT, et al. Carotid Artery Tortuosity Is Associated with Connective Tissue Diseases. *AJNR Am J Neuroradiol.* 2019;40: 1738–1743.
47. Tapp RJ, Owen CG, Barman SA, Welikala RA, Foster PJ, Whincup PH, et al. Associations of Retinal Microvascular Diameters and Tortuosity With Blood Pressure and Arterial Stiffness. *Hypertension.* 2019. pp. 1383–1390. doi:10.1161/hypertensionaha.119.13752

48. Heneghan C, Flynn J, O'Keefe M, Cahill M. Characterization of changes in blood vessel width and tortuosity in retinopathy of prematurity using image analysis. *Med Image Anal.* 2002;6: 407–429.
49. Pruijm M, Ponte B, Ackermann D, Vuistiner P, Paccaud F, Guessous I, et al. Heritability, determinants and reference values of renal length: a family-based population study. *Eur Radiol.* 2013;23: 2899–2905.
50. Ponte B, Pruijm M, Ackermann D, Vuistiner P, Eisenberger U, Guessous I, et al. Reference values and factors associated with renal resistive index in a family-based population study. *Hypertension.* 2014;63: 136–142.
51. Firmann M, Mayor V, Vidal PM, Bochud M, Pécoud A, Hayoz D, et al. The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. *BMC Cardiovasc Disord.* 2008;8: 6.
52. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. *PLOS Medicine.* 2015. p. e1001779. doi:10.1371/journal.pmed.1001779
53. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature.* 2018;562: 203–209.
54. Pistis G, Porcu E, Vrieze SI, Sidore C, Steri M, Danjou F, et al. Rare variant genotype imputation with thousands of study-specific whole-genome sequences: implications for cost-effective study designs. *Eur J Hum Genet.* 2015;23: 975–983.
55. Bankhead P, Scholfield CN, McGeown JG, Curtis TM. Fast retinal vessel detection and measurement using wavelets and edge location refinement. *PLoS One.* 2012;7: e32435.
56. Al-Diri B, Hunter A, Steel D, Habib M, Hudaib T, Berry S. REVIEW - a reference data set for retinal vessel profiles. *Conf Proc IEEE Eng Med Biol Soc.* 2008;2008: 2262–2265.
57. Smedby O, Högman N, Nilsson S, Erikson U, Olsson AG, Walldius G. Two-dimensional tortuosity of the superficial femoral artery in early atherosclerosis. *J Vasc Res.* 1993;30: 181–191.
58. Abdalla M, Hunter A, Al-Diri B. Quantifying retinal blood vessels' tortuosity — Review. 2015 Science and Information Conference (SAI). 2015. doi:10.1109/sai.2015.7237216
59. Adrian Galdran, André Anjos, José Dolz, Hadi Chakor, Hervé Lombaert, Ismail Ben Ayed. The Little W-Net That Could: State-of-the-Art Retinal Vessel Segmentation with Minimalistic Models. *arXiv.* 2020. doi:The Little W-Net That Could: State-of-the-Art Retinal Vessel Segmentation with Minimalistic Models
60. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. Genome-wide genetic data on ~500,000 UK Biobank participants. *bioRxiv.* 2017. p. 166298. doi:10.1101/166298
61. Pain O, Dudbridge F, Ronald A. Are your covariates under control? How normalization can re-introduce covariate effects. *Eur J Hum Genet.* 2018;26: 1194–1201.
62. Myers TA, Chanock SJ, Machiela MJ. LDlinkR: An R Package for Rapidly Calculating Linkage Disequilibrium Statistics in Diverse Populations. *Frontiers in Genetics.* 2020. doi:10.3389/fgene.2020.00157
63. Kang HM. EFACTS: efficient and parallelizable association container toolbox. 2016. Available: <https://genome.sph.umich.edu/wiki/EFACTS>
64. Benjamini Y, Hochberg Y. On the Adaptive Control of the False Discovery Rate in Multiple Testing with Independent Statistics. *Journal of Educational and Behavioral Statistics.* 2000. p. 60. doi:10.2307/1165312
65. Zheng J, Erzurumluoglu AM, Elsworth BL, Kemp JP, Howe L, Haycock PC, et al. LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. *Bioinformatics.* 2017;33: 272–279.
66. Krefl D, Bergmann S. PascalX v0.0.1. 2021. doi:10.5281/zenodo.4429922
67. Lamparter D, Marbach D, Rueedi R, Kutalik Z, Bergmann S. Fast and Rigorous Computation of Gene and Pathway Scores from SNP-Based Summary Statistics. *PLoS Comput Biol.* 2016;12: e1004714.
68. Kinsella RJ, Kähäri A, Haider S, Zamora J, Proctor G, Spudich G, et al. Ensembl BioMarts: a hub for data retrieval across taxonomic space. *Database.* 2011;2011: bar030.
69. Huang J, Howie B, McCarthy S, Memari Y, Walter K, Min JL, et al. Improved imputation of low-frequency and rare variants using the UK10K haplotype reference panel. *Nat Commun.* 2015;6: 8111.
70. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. *Bioinformatics.* 2011;27: 1739–1740.
71. Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, et al. The Genotype-Tissue Expression (GTEx) project. *Nat Genet.* 2013;45: 580–585.

72. Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res.* 2019;47: D1005–D1012.
73. Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for Mendelian randomization. *Stat Methods Med Res.* 2017;26: 2333–2355.
74. Smith GD, Ebrahim S. “Mendelian randomization”: can genetic epidemiology contribute to understanding environmental determinants of disease? *Int J Epidemiol.* 2003;32: 1–22.
75. Genome-wide Repository of Associations Between SNPs and Phenotypes. In: National Institutes of Health (NIH) [Internet]. [cited Feb 2021]. Available: <https://grasp.nhlbi.nih.gov/>
76. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol.* 2013;37: 658–665.
77. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. *Int J Epidemiol.* 2017;46: 1734–1739.
78. Kuwabara I, Kuwabara Y, Yang R-Y, Schuler M, Green DR, Zuraw BL, et al. Galectin-7 (PIG1) exhibits pro-apoptotic function through JNK activation and mitochondrial cytochrome c release. *J Biol Chem.* 2002;277: 3487–3497.
79. Turczyńska KM, Swärd K, Hien TT, Wohlfahrt J, Mattisson IY, Ekman M, et al. Regulation of smooth muscle dystrophin and synaptopodin 2 expression by actin polymerization and vascular injury. *Arterioscler Thromb Vasc Biol.* 2015;35: 1489–1497.
80. Karouta C, Kucharski R, Hardy K, Thomson K, Maleszka R, Morgan I, et al. Transcriptome-based insights into gene networks controlling myopia prevention. *FASEB J.* 2021;35: e21846.
81. Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. *Angiogenesis.* 2006;9: 225–30; discussion 231.
82. J.M.B. Sand, F. Genovese, N.S. Gudmann, M.A. Karsdal. Type IV collagen. In: Karsdal MA, editor. *Biochemistry of Collagens, Laminins and Elastin* 2nd edition. 2019.
83. Shih Y-P, Sun P, Wang A, Lo SH. Tensin1 positively regulates RhoA activity through its interaction with DLC1. *Biochim Biophys Acta.* 2015;1853: 3258–3265.
84. Fonović M, Turk B. Cysteine cathepsins and extracellular matrix degradation. *Biochim Biophys Acta.* 2014;1840: 2560–2570.
85. Yang D, Sun C, Zhang J, Lin S, Zhao L, Wang L, et al. Proliferation of vascular smooth muscle cells under inflammation is regulated by NF- κ B p65/microRNA-17/RB pathway activation. *Int J Mol Med.* 2018;41: 43–50.
86. Dick MK, Miao JH, Limaieim F. Histology, fibroblast. *StatPearls* [Internet]. 2021. Available: <https://www.ncbi.nlm.nih.gov/books/NBK541065/>
87. Kur J, Newman EA, Chan-Ling T. Cellular and physiological mechanisms underlying blood flow regulation in the retina and choroid in health and disease. *Prog Retin Eye Res.* 2012;31: 377–406.
88. Wakisaka M, Nagao T. Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy. *Glycobiology.* 2017;27: 691–695.
89. Uemura A, Fruttiger M, D’Amore PA, De Falco S, Jousen AM, Sennlaub F, et al. VEGFR1 signaling in retinal angiogenesis and microinflammation. *Prog Retin Eye Res.* 2021;84: 100954.
90. Won K-J, Lee KP, Kim D-K, Jung SH, Lee C-K, Lee DH, et al. Monoclonal antibody against α -actinin 4 from human umbilical vein endothelial cells inhibits endothelium-dependent vasorelaxation. *J Vasc Res.* 2013;50: 210–220.
91. Zenteno JC, Crespí J, Buentello-Volante B, Buil JA, Bassaganyas F, Vela-Segarra JI, et al. Next generation sequencing uncovers a missense mutation in COL4A1 as the cause of familial retinal arteriolar tortuosity. *Graefes Arch Clin Exp Ophthalmol.* 2014;52: 1789–1794.
92. Vahedi K, Alamowitch S. Clinical spectrum of type IV collagen (COL4A1) mutations: a novel genetic multisystem disease. *Curr Opin Neurol.* 2011;24: 63–68.
93. Trouillet A, Lorach H, Dubus E, El Mathari B, Ivkovic I, Dégardin J, et al. Col4a1 mutation generates vascular abnormalities correlated with neuronal damage in a mouse model of HANAC syndrome. *Neurobiol Dis.* 2017;100: 52–61.
94. McGinnis R, Steinthorsdottir V, Williams NO, Thorleifsson G, Shooter S, Hjartardottir S, et al. Variants in the fetal genome near FLT1 are associated with risk of preeclampsia. *Nat Genet.* 2017;49: 1255–1260.
95. Al-Jameil N, Aziz Khan F, Fareed Khan M, Tabassum H. A brief overview of preeclampsia. *J Clin Med Res.* 2014;6: 1–7.

96. Nagy ZZ. Review of the ophthalmic symptoms of preeclampsia. *Developments in Health Sciences*. 2020. pp. 21–23. doi:10.1556/2066.2020.00005
97. Lupton SJ, Chiu CL, Hodgson LAB, Tooher J, Ogle R, Wong TY, et al. Changes in retinal microvascular caliber precede the clinical onset of preeclampsia. *Hypertension*. 2013;62: 899–904.
98. Soma-Pillay P, Pillay R, Wong TY, Makin JD, Pattinson RC. The effect of pre-eclampsia on retinal microvascular caliber at delivery and post-partum. *Obstet Med*. 2018;11: 116–120.
99. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur Heart J*. 2017;38: 2459–2472.
100. Han H-C. Twisted blood vessels: symptoms, etiology and biomechanical mechanisms. *J Vasc Res*. 2012;49: 185–197.
101. Kwa VIH, van der Sande JJ, Stam J, Tijmes N, Vrooland JL, Amsterdam Vascular Medicine Group. Retinal arterial changes correlate with cerebral small-vessel disease. *Neurology*. 2002;59: 1536–1540.
102. Tapp RJ, Owen CG, Barman SA, Welikala RA, Foster PJ, Whincup PH, et al. Retinal Vascular Tortuosity and Diameter Associations with Adiposity and Components of Body Composition. *Obesity*. 2020;28: 1750–1760.
103. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A*. 2005;102: 15545–15550.
104. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. *Nat Commun*. 2017;8: 1826.
105. Maguire LH, Handelman SK, Du X, Chen Y, Pers TH, Speliotes EK. Genome-wide association analyses identify 39 new susceptibility loci for diverticular disease. *Nat Genet*. 2018;50: 1359–1365.
106. Osman W, Low S-K, Takahashi A, Kubo M, Nakamura Y. A genome-wide association study in the Japanese population confirms 9p21 and 14q23 as susceptibility loci for primary open angle glaucoma. *Hum Mol Genet*. 2012;21: 2836–2842.
107. Sim X, Ong RT-H, Suo C, Tay W-T, Liu J, Ng DP-K, et al. Transferability of type 2 diabetes implicated loci in multi-ethnic cohorts from Southeast Asia. *PLoS Genet*. 2011;7: e1001363.
108. German CA, Sinsheimer JS, Klimentidis YC, Zhou H, Zhou JJ. Ordered multinomial regression for genetic association analysis of ordinal phenotypes at Biobank scale. *Genet Epidemiol*. 2020;44: 248–260.
109. Slager SL, Skibola CF, Di Bernardo MC, Conde L, Broderick P, McDonnell SK, et al. Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. *Blood*. 2012;120: 843–846.
110. Tedja MS, Wojciechowski R, Hysi PG, Eriksson N, Furlotte NA, Verhoeven VJM, et al. Genome-wide association meta-analysis highlights light-induced signaling as a driver for refractive error. *Nat Genet*. 2018;50: 834–848.
111. Mehta NN. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Circulation. Cardiovascular genetics*. 2011. pp. 327–329.
112. Kathiresan S, Myocardial Infarction Genetics Consortium, Voight BF, Purcell S, Musunuru K, Ardissino D, et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. *Nat Genet*. 2009;41: 334–341.
113. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. *Nat Genet*. 2013;45: 1452–1458.
114. den Hoed M, Eijgelsheim M, Esko T, Brundel BJJM, Peal DS, Evans DM, et al. Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. *Nat Genet*. 2013;45: 621–631.
115. Kichaev G, Bhatia G, Loh P-R, Gazal S, Burch K, Freund MK, et al. Leveraging Polygenic Functional Enrichment to Improve GWAS Power. *Am J Hum Genet*. 2019;104: 65–75.
116. Wain LV, Shrine N, Miller S, Jackson VE, Ntalla I, Soler Artigas M, et al. Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank. *Lancet Respir Med*. 2015;3: 769–781.
117. Khawaja AP, UK Biobank Eye and Vision Consortium, Cooke Bailey JN, Wareham NJ, Scott RA, Simcoe M, et al. Genome-wide analyses identify 68 new loci associated with intraocular pressure and improve risk prediction for primary open-angle glaucoma. *Nature Genetics*. 2018. pp. 778–782. doi:10.1038/s41588-018-0126-8
118. Stapleton CP, Heinzl A, Guan W, van der Most PJ, van Setten J, Lord GM, et al. The impact of donor and recipient common clinical and genetic variation on estimated glomerular filtration rate in a European renal transplant

population. *Am J Transplant*. 2019;19: 2262–2273.

119. Warren HR, Evangelou E, Cabrera CP, Gao H, Ren M, Mifsud B, et al. Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. *Nat Genet*. 2017;49: 403–415.
120. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, et al. Genome-wide association study identifies eight loci associated with blood pressure. *Nat Genet*. 2009;41: 666–676.
121. Wain LV, Verwoert GC, O'Reilly PF, Shi G, Johnson T, Johnson AD, et al. Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. *Nat Genet*. 2011;43: 1005–1011.
122. Giri A, Hellwege JN, Keaton JM, Park J, Qiu C, Warren HR, et al. Trans-ethnic association study of blood pressure determinants in over 750,000 individuals. *Nat Genet*. 2019;51: 51–62.
123. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, et al. Genome-wide association study of blood pressure and hypertension. *Nat Genet*. 2009;41: 677–687.
124. Craig JE, Han X, Qassim A, Hassall M, Cooke Bailey JN, Kinzy TG, et al. Multitrait analysis of glaucoma identifies new risk loci and enables polygenic prediction of disease susceptibility and progression. *Nat Genet*. 2020;52: 160–166.
125. Seshadri S, DeStefano AL, Au R, Massaro JM, Beiser AS, Kelly-Hayes M, et al. Genetic correlates of brain aging on MRI and cognitive test measures: a genome-wide association and linkage analysis in the Framingham Study. *BMC Med Genet*. 2007;8 Suppl 1: S15.

Supplemental References

1. Bankhead P, Scholfield CN, McGeown JG, Curtis TM. Fast retinal vessel detection and measurement using wavelets and edge location refinement. *PLoS One*. 2012;7: e32435.
2. Galdran A, Anjos A, Dolz J, Chakor H, Lombaert H, Ayed IB. The Little W-Net That Could: State-of-the-Art Retinal Vessel Segmentation with Minimalistic Models. 2020. Available: <http://arxiv.org/abs/2009.01907>
3. Lee CH, Eskin E, Han B. Increasing the power of meta-analysis of genome-wide association studies to detect heterogeneous effects. *Bioinformatics*. 2017;33: i379–i388.
4. Veluchamy A, Ballerini L, Vitart V, Schraut KE, Kirin M, Campbell H, et al. Novel Genetic Locus Influencing Retinal Venular Tortuosity Is Also Associated With Risk of Coronary Artery Disease. *Arterioscler Thromb Vasc Biol*. 2019;39: 2542–2552.
5. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nat Genet*. 2011;43: 333–338.
6. C4D Consortium. A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. *Nat Genet*. 2011;43: 339–344.
7. Osman W, Low S-K, Takahashi A, Kubo M, Nakamura Y. A genome-wide association study in the Japanese population confirms 9p21 and 14q23 as susceptibility loci for primary open angle glaucoma. *Hum Mol Genet*. 2012;21: 2836–2842.
8. Craig JE, Han X, Qassim A, Hassall M, Cooke Bailey JN, Kinzy TG, et al. Multitrait analysis of glaucoma identifies new risk loci and enables polygenic prediction of disease susceptibility and progression. *Nat Genet*. 2020;52: 160–166.
9. German CA, Sinsheimer JS, Klimentidis YC, Zhou H, Zhou JJ. Ordered multinomial regression for genetic association analysis of ordinal phenotypes at Biobank scale. *Genet Epidemiol*. 2020;44: 248–260.
10. Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, Erlich HA, et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. *Nat Genet*. 2009;41: 703–707.
11. Plagnol V, Howson JMM, Smyth DJ, Walker N, Hafler JP, Wallace C, et al. Genome-wide association analysis of autoantibody positivity in type 1 diabetes cases. *PLoS Genet*. 2011;7: e1002216.
12. Shah S, Henry A, Roselli C, Lin H, Sveinbjörnsson G, Fatemifar G, et al. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. *Nat Commun*. 2020;11: 163.

13. Dubois PCA, Trynka G, Franke L, Hunt KA, Romanos J, Curtotti A, et al. Multiple common variants for celiac disease influencing immune gene expression. *Nat Genet.* 2010;42: 295–302.
14. Jin Y, Birlea SA, Fain PR, Ferrara TM, Ben S, Riccardi SL, et al. Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. *Nat Genet.* 2012;44: 676–680.
15. Kichaev G, Bhatia G, Loh P-R, Gazal S, Burch K, Freund MK, et al. Leveraging Polygenic Functional Enrichment to Improve GWAS Power. *Am J Hum Genet.* 2019;104: 65–75.
16. Comuzzie AG, Cole SA, Laston SL, Voruganti VS, Haack K, Gibbs RA, et al. Novel genetic loci identified for the pathophysiology of childhood obesity in the Hispanic population. *PLoS One.* 2012;7: e51954.
17. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, et al. Genome-wide association study of blood pressure and hypertension. *Nat Genet.* 2009;41: 677–687.
18. Giri A, Hellwege JN, Keaton JM, Park J, Qiu C, Warren HR, et al. Trans-ethnic association study of blood pressure determinants in over 750,000 individuals. *Nat Genet.* 2019;51: 51–62.
19. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, et al. Genome-wide association study identifies eight loci associated with blood pressure. *Nat Genet.* 2009;41: 666–676.
20. Wain LV, Verwoert GC, O'Reilly PF, Shi G, Johnson T, Johnson AD, et al. Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. *Nat Genet.* 2011;43: 1005–1011.
21. Davies G, Lam M, Harris SE, Trampush JW, Luciano M, Hill WD, et al. Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. *Nat Commun.* 2018;9: 2098.
22. Krefl D, Bergmann S. PascalX v0.0.1. 2021. doi:10.5281/zenodo.4429922
23. Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, et al. The Genotype-Tissue Expression (GTEx) project. *Nat Genet.* 2013;45: 580–585.
24. Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmoish M, et al. GeneCards Version 3: the human gene integrator. *Database* . 2010;2010: baq020.
25. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res.* 2018;47: D607–D613.

SUPPLEMENTAL MATERIAL

(intended for publication as an online data supplement)

GWAS of Retinal Vessel Tortuosity Identifies 173 Novel Loci Revealing Genes and Pathways Associated with Vascular Pathomechanics and Cardiometabolic Diseases

TABLE OF CONTENTS

SUPPLEMENTAL DATASETS	0
SUPPLEMENTAL METHODS	1
Text 1: Quality Control in tortuosity measurements	1
Text 2: DF and other tortuosity measures	1
Definition of DF	1
Definitions of six, alternative, curvature-based measures	1
PCA of DF and curvature-based measurements	2
Heritability of DF and curvature-based measurements	Erreur ! Signet non défini.
Enrichment analysis of curvature-based measurement associations	3
Text 3: Distribution of DF	4
DF tortuosity across cohorts	5
Stratified DF analysis: sex, age and vessel type	5
Text 4: Deep Learning classification of arteries and veins	6
Accuracy of vessel type classification	6
Censoring unclearly classified vessels	7
GWAS with random vessel type calling	7
Text 5: Replication Analysis	8
Correlation of effect sizes in the meta-cohort	8
Replication of hits in the meta-cohort	8
SUPPLEMENTAL RESULTS	10
Text 6: Baseline Characteristics	10
Text 7: Correlation with disease status	10
Text 8: Replication of known hits	10
Text 9: Vessel-type comparisons for SNPs, Genes and Pathways	13
Text 10: Genetic associations with disease and risk	14
Tortuosity variants associated with disease outcome	14
Tortuosity variants associated with disease risk factors	14
Text 11: Mendelian Randomization	15
Text 12: ACTN4 and COL4A2 over-expression	16
Text 13: Full gene set enrichment results	16

39 SUPPLEMENTAL DATASET

- 40 [Supplemental Dataset 1 - 175 lead SNPs](#)
- 41 [Supplemental Dataset 2 - overlap with GWAS Catalog \(SNPs in LD\)](#)
- 42 [Supplemental Dataset 3 - overlap with GWAS Catalog \(SNPs with matching rsIDs\)](#)
- 43 [Supplemental Dataset 4A - significant SNPs \(combined\)](#)
- 44 [Supplemental Dataset 4B - significant SNPs \(artery\)](#)
- 45 [Supplemental Dataset 4C - significant SNPs \(vein\)](#)
- 46 [Supplemental Dataset 5 - replication of lead SNPs](#)
- 47 [Supplemental Dataset 6A - gene scores \(combined\)](#)
- 48 [Supplemental Dataset 6B - gene scores \(artery\)](#)
- 49 [Supplemental Dataset 6C - gene scores \(vein\)](#)
- 50 [Supplemental Dataset 7A - gene set enrichment \(combined\)](#)
- 51 [Supplemental Dataset 7B - gene set enrichment \(artery\)](#)
- 52 [Supplemental Dataset 7C - gene set enrichment \(vein\)](#)

53 SUPPLEMENTAL METHODS

54 Text 1: Quality Control in tortuosity measurements

55 The quality control (QC) procedure is performed during data extraction. The objective is to remove
56 (i) lower quality images and (ii) images containing artifacts. QC relies on thresholding being applied
57 to two distributions: 1) Distribution of the total number of equally spaced diameters that were fitted
58 to the vessels of each eye. Images between with values 11 000 and 20 000 passed QC. 2)
59 Distribution of the number of vessels contained in each eye. Images with values between 100 and
60 250 passed QC. By visual inspection, we fine tuned these thresholds to discriminate (i) low-quality
61 images that were too dark, too light, out of focus (lower-bound thresholds), or (ii) images that
62 contained spurious vessels, i.e., artifacts of the picture that were being erroneously segmented as
63 vessels (higher-bound thresholds). Images that pass QC (roughly two out of three) are further
64 processed to extract several tortuosity measures.

65 Text 2: DF and other tortuosity measures

66 **Definition of DF**

67 We consider a vessel as a curve in a two dimensional space on the interval $[t_0, t_1]$. For a given curve
68 there are different tortuosity measures: The simplest one, the "Distance Factor" (DF), is calculated
69 as the total arc length over total chord length. This measure computes the tortuosity of the segment
70 by examining how long the curve is relative to its chord length.

$$71 \quad DF = \frac{s(C)}{\text{chord}(C)}$$

72
73 Let $s(C)$ be the arc length of the curve C , and $\text{chord}(C)$ its chord length:

$$74 \quad s(C) = \int_{t_0}^{t_1} \sqrt{x'(t)^2 + y'(t)^2} dt \quad , \quad \text{chord}(C) = \sqrt{(x(t_1) - x(t_0))^2 + (y(t_1) - y(t_0))^2}$$

75 where the prime denotes derivation with respect to t .

76 **Definitions of six, alternative, curvature-based measures**

77 A first curvature-based tortuosity measure is obtained as the integral over the absolute value of
78 curvature along the entire curvature:

$$79 \quad \tau_2 = \int_{t_0}^{t_1} |\kappa(t)| dt \quad , \quad \text{where the curvature is defined as: } |\kappa(\square)| = \frac{|x'(\square)y''(\square) - x''(\square)y'(\square)|}{[y'(\square)^2 + x'(\square)^2]^{3/2}}$$

80 This is equivalent to the inverse curvature radius $R(t)$, i.e. the radius of a circle that is tangent to the
81 curve at t : $|\kappa| = 1/R$.

82 A second tortuosity measure is the integral over the curvature squared along the entire curve:

83


$$\tau_3 = \int_{t_0}^{t_1} \kappa(t)^2 dt$$

84 Finally, four tortuosity measures arise from normalizing and τ_3 by division through either the curve
85 or the arc length:

$$\begin{aligned} 86 \quad \tau_4 &= \int_{t_0}^{t_1} \frac{|\kappa(t)|}{s(C)} dt, \quad \tau_5 = \int_{t_0}^{t_1} \frac{\kappa(t)^2}{s(C)} dt, \quad \tau_6 = \int_{t_0}^{t_1} \frac{|\kappa(t)|}{\text{chord}(C)} dt, \quad \tau_7 \\ 87 \quad &= \int_{t_0}^{t_1} \frac{\kappa(t)^2}{\text{chord}(C)} dt \end{aligned}$$

88 We note that, by definition, τ_2 and τ_3 depend on the length of the curve (with non-zero curvature).
89 In the case of vessels with constant curvature radius: $\tau_2 = s(C)/R$ and $\tau_3 = s(C)/R^2$. Our analysis
90 shows that τ_2 differs from other measures the most, followed by τ_3 , while τ_{4-7} are indeed quite
91 similar to each other (see Supplemental Figure 1)

92 PCA of DF and curvature-based measurements



93

94

95

96 **Supplemental Figure 1 | Dimensionality reduction on tortuosity measurements across**
97 **62 751 individuals.** Left: Hierarchical clustering of the pairwise correlations-matrix. Correlations
98 are measured using the Pearson correlation coefficient. Right: We performed dimensionality
99 reduction using a Principal Component Analysis (PCA) approach and plotted PC2 against PC1.

100 Heritability of DF and curvature-based measurements

Measure	h^2_{SNP}	Lambda GC	Mean Ch^2	Intercept	Ratio
DF (Distance Factor)	0.25 (0.025)	1.14	1.31	1.01 (0.01)	0.03 (0.03)
τ_2	0.11 (0.011)	1.08	1.11	0.98 (0.01)	< 0
τ_3	0.11 (0.012)	1.09	1.13	0.99 (0.01)	< 0
τ_4	0.12 (0.011)	1.11	1.15	1.00 (0.01)	0.02 (0.05)
τ_5	0.12 (0.011)	1.10	1.14	1.00 (0.01)	< 0
τ_6	0.13 (0.012)	1.11	1.16	1.00 (0.01)	0.01 (0.04)
τ_7	0.12 (0.011)	1.10	1.15	1.00 (0.01)	< 0

101 **Supplemental Table 1 | SNP-based heritability of alternative tortuosity measures.** h^2_{SNP} is the
102 portion of phenotypic variance cumulatively explained by the SNPs. Traits defined by the six

103 alternative tortuosity measures were less heritable than the one defined by the Distance Factor.
104 Λ GC is the measure of inflation (it measures the effect of confounding and polygenicity
105 acting on the trait). *Intercept* is the LD Score regression intercept (values close to 1 indicates little
106 influence of confounders, mostly of population stratification). *Ratio* is the ratio of the proportion of
107 the inflation in the $Mean Ch^2$ that is not due to polygenicity (a ratio close to, or smaller than, 0 is
108 desirable as it indicates low inflation from population stratification). SE are given in parentheses.

109 **Enrichment analysis of curvature-based measurement associations**

110 The alternative tortuosity measures have less significant SNPs, genes and pathways overall
111 compared to the distance factor, but harbor few unique pathways, among which is a pathway, in \square_6 ,
112 called “abnormal cardiac ventricle morphology” ($-\log_{10} p=5.8$) from the human phenotype oncology
113 (HP) group. Being the gene scores of them highly significant in our analysis.


114 On the phenotypic level, we found that tau 2 (total curvature) is least similar to all the others, that
115 tau 3 (total squared curvature) is comparably similar to the DF, and that tau 4-7 (average curvature)
116 form a distinct cluster of similar measurements.

117 Here, despite all alternative measures having significantly lower SNP-wise heritability than the DF,
118 we found eighteen genes (Figure 2a) and four pathways (Figure 2b) specific to them, i.e. not present
119 in the DF. Among them are genes with potentially relevant annotations, as described by *GeneCards*
120 [24]: OCA2 (Oculocutaneous Albinism 2), the overall top hit, is a determinant of eye color, and
121 associated with albinism. TRIOBP, the most significant specific hit in tau 2, is a structural protein
122 binding to F-actin, and acts as a stabilizer of the cytoskeleton. LGALS1 is implicated in modulation
123 of cell-cell and cell-matrix interactions, and thus a structural protein that might affect, among other
124 things, vessel bendiness. GLIS3 is a zinc-finger protein that plays a role in eye development.


125 We also identified a cluster of four genes (LRIT1, LRIT2, CDHR1, RGR) on locus 10q23
126 (Supplemental Figure 2c) through STRING [25], all of which have been associated with eye
127 disorders. RGR has been associated with Retinitis pigmentosa. LRIT1, LRIT2 and CDHR1 have
128 been associated with nanophthalmos, a developmental eye disorder characterized by small eyes.
129 Molecularly, CDHR1 is a calcium-dependent cell adhesion molecule expressed in blood vessels,
130 and thus likely to affect their morphology.

131 Two out of the four pathways both specific to the average curvature measures, are plausibly related
132 to vascular changes. The first, GO_CELL_JUNCTION_ORGANISATION, is a GO set of genes
133 influencing the tightness of connection between neighboring cells. The second,
134 HP_ABNORMAL_CARDIAC_VENTRICLE_MORPHOLOGY, Human Phenotype Ontology set of
135 genes associated with disease-related abnormalities in cardiovascular tissue. This pathway has
136 three genes strongly driving the signal: 1) RYR1, a sarcoplasmic reticulum calcium release channel,
137 2) MYOZ2, a sarcomeric protein involved in calcium-dependent signal transduction, and 3) FADD,
138 an apoptotic adapter molecule. Interestingly, no pathways were specific to the most dissimilar
139 measure, tau 2.


140 In summary, first, this confirms two observations we made on the phenotype level: 1) tau 2 with
141 twelve unique gene hits is the most dissimilar from the others, and 2) tau 4-7 are almost identical
142 and can probably be treated as one measure. Second, we identified relevant genes and pathways
143 specific to these measures, indicating that they may capture disease-relevant vascular changes the
144 DF is not sensitive to.



145 a.
146
147 b.
148



149 c.
150




151
187

Supplemental Figure 2 | Genes and pathways specific to alternative tortuosity measures. We use a Bonferroni-corrected $-\log_{10}$ p-value significance threshold of 5.71 for genes, and 5.79 for pathways. Significant hits are marked with an asterisk (*). The tables are ordered by maximal significance.

- a. All the genes and pathways that are significant in one of the alternative tortuosity measures, but not in the distance factor (DF), are displayed. There are twelve genes specific to tau 2, one to tau 3, and five to the very similar measures tau 4-7.
- b. Four pathways are specific to the alternative tortuosity measurements: one in tau 3, three in tau 4-7, but none were found in tau 2. They contain 577, 10, 170, and 394 scored genes respectively.
- c. STRING [25] cluster of four genes (LRIT1, LRIT2, CDHR1, RGR), all of which reside on locus 10q23, and have been associated with eye pathologies.




188 **Text 3: Distribution of DF**

189 **DF tortuosity across cohorts**



190 **Supplemental Figure 3 | Distribution of DF tortuosity across cohorts.** UK Biobank mean±SD =
 191 1.030±6.5×10⁻³; SKIPOGH mean±SD = 1.029±6.2×10⁻³; *OphthalmoLaus* mean±SD=1.034±6.0×10⁻³.
 192

193 **Stratified DF analysis: sex, age and vessel type**



194
213

214 Text 4: Deep Learning classification of arteries and veins

215 Accuracy of vessel type classification

216 LWNET [2] converts raw RGB fundus images into a categorical image of three categories, which are
217 defined by the following RGB values: 1) artery: red (255,0,0), 2) vein: blue (0,0,255) and 3)
218 background: black (0,0,0) (Supplemental Figure 5a).


219 We used LWNET to perform automatic artery-vein classification on our 44 ground truth images
220 (fundus images for which we have manual annotation by ophthalmologist HA), and subsequently
221 extracted the resulting categories for vessel segment centerlines, which we previously computed
222 using ARIA software. For all the centerlines of the 44 images we computed a segment score based
223 on individual centerline pixel classifications as follows:

$$224 \quad S = (\Sigma \text{red} - \Sigma \text{blue})/N_{\text{pixel}}$$

225 A ROC curve and its derived AUC measure was computed on the resulting vector of segment scores
226 using logistic regression. This resulted in AUC=0.93. Accuracy was computed simply as:

$$227 \quad \text{acc} = T/(T + F)$$

228 where T is the number of correctly categorized segments, and F the number of wrongly categorized
229 segments. We chose not to censor any segments, and called classification based on the simple rule
230 that vessels with $S > 0$ were called arteries and vessels with $S < 0$ were called veins. This resulted in
231 $\text{acc} = 0.88$.



232 **Supplemental Figure 5 | AUC and accuracy of artery-vein classification.** a) LWNET output
233 image consists of 3 categories: artery, vein and background. b) ROC curve when not censoring
234 any segments, resulting in AUC=0.93 and accuracy=0.88. c) AUC and accuracy could be further
235 improved by censoring the most unclearly classified vessel segments. d) Median length of
236 censored segments is significantly shorter than the overall median length, which could be the
237 reason why we found decreased heritability in our traits in the censoring approach.
238

239 Censoring unclearly classified vessels


240 Performance could be further increased by removing segments with more uncertain scores (i.e.
241 close to zero). We increasingly removed the vessel segments with the lowest absolute score, and
242 measured how this influenced AUC and accuracy based on the remaining segments. We found that,
243 while AUC shows only moderate increase, accuracy increased from 0.88, without censoring, to
244 almost 0.94 when removing a third of the segments (Supplemental Figure 5c). However, we also
245 found that by doing this we predominantly removed shorter segments (see Supplemental Figure 5d).

246 We then ran a GWAS based on only the approximately $\frac{2}{3}$ most confidently scored segments in the
247 UK Biobank, and found a doubling of the number of Genome-Wide-significant hits for arteries
248 (+117%) (the amount of signal for veins was, on the contrary, not affected). Further analysis, though,
249 showed an inflation in the Q-Q plot of the artery-specific GWAS based on high-confidence vessels
250 only. This was confirmed by analysis of the parameters of the LD Score Regression, which indicated
251 a loss in the ability of the results to explain (SNP)-based heritability of the trait (h_{SNP}^2 dropped from
252 0.25 to 0.11), coupled with genomic inflation (intercept had increased from 1.01 to 1.93). For these
253 reasons, all vessels identified as arteries or veins were used in the respective vessel-type-specific
254 analysis, as selecting vessels with the highest identification score had brought marginal
255 improvement to the already high AUC at the price of introducing a bias.

256 GWAS with random vessel type calling

257 We estimated the independence of the signals arising from the above-described classification of
258 arteries and veins as follows: we modified the pipeline to perform random calling of arteries and
259 veins (by shuffling the vector of artery and veins scores computed for each eye). We then compared
260 the similarity in the signal between two random vessel-type GWAS: we clearly show that the effect
261 sizes (which are significant in at least one of the two GWAS) are nearly identical ($r=0.99$, $p=4 \cdot 10^{-82}$)
262 when the vessel type calling is random. By comparison, the effect sizes are much less coupled
263 ($r=0.76$, $p=1 \cdot 10^{-20}$) in the artery- and vein-specific GWAS based on the vessel type calling procedure
264 that has been described

265




266

267 **Supplemental Figure 6 | Correlation in the effect sizes from arteries and veins.** To support
268 the effectiveness of our vessel type calling procedure, we performed random calling of arteries and
269 veins (by shuffling the vector of artery and veins scores computed for each eye). We then
270 performed two random vessel-type GWAS (left) and compared the results with the artery and vein-
271 specific GWAS (right): we clearly show that the effect sizes (which are significant in at least one of
272 the two GWAS) are less coupled when the vessel type is not random.

273 Text 5: Replication Analysis

274 **Correlation of effect sizes in the meta-cohort**

275 Of the 136 SNP shared between the discovery and replication studies, the sign of the effect sizes
 276 was concordant in 90 (binomial test $p = 5.0 \times 10^{-5}$). We observed a Pearson correlation of $r = 0.53$
 277 ($p = 1.2 \times 10^{-11}$) between the effect size estimates in the two studies. When some outliers are
 278 removed, the correlation drops from $r = 0.53$ to $r = 0.36$, remaining highly significant.



279 **Supplemental Figure 7 | Extended plot for correlation of effect sizes between discovery and**
 280 **replication cohort.** Left: correlation of effect sizes in the discovery and replication cohort as
 281 shown in the main text of the manuscript. Right: same plot without considering the outlier. We
 282 removed one outlier in the top-right quadrant, corresponding to rs187691758. This shows the
 283 robustness of the result: even though the Pearson correlation dropped from $r=0.53$ to $r=0.36$, it
 284 remained highly significant ($p=1.18 \cdot 10^{-5}$). Out of the 135 remaining SNPs, 89 shared the sign in
 285 effect size (binomial test $p=2.94 \cdot 10^{-6}$).
 286
 287

288 **Replication of hits in the meta-cohort**


290 We performed a meta-analysis of the two cohorts OphtalmoLaus (N=514) and SKIPOGH (N=397),
 291 using both a fixed-effects model (see below) and a random-effects model [3]. For each SNP, the
 292 fixed-effects model computes meta-values of the standard error (SE) and effect size summary
 293 statistics, with the meta effect size being a weighted average of individual effect sizes, weighted by
 294 their corresponding inverse SE:

$$295 \quad \beta_{meta} = \frac{\sum_i^M w_i \times \beta_i}{\sum_i^M w_i} \quad SE_{meta} = \frac{1}{\sqrt{\sum_i^M w_i}} \quad \text{where } w_i = \frac{1}{SE_i^2}, \text{ and } M \text{ the number of cohorts}$$

296 The resulting SNP P-value is then given by a two-tailed t-statistic

$$297 \quad t = \frac{\beta_{meta}}{SE_{meta}} \text{ with } \sum_i^M N_i - 1 \text{ degrees of freedom (911 in our case)}$$

298 The following two figures present the results from both meta-analyses, and the subsequent gene
 299 and pathway scoring based on their results. All replication is performed on the combined-vessel
 300 median distance factor phenotype.




302

303

304 **Supplemental Figure 8 | Replication meta-**
 305 **analysis with fixed-effects.**

306 Meta-GWAS summary statistics were
 307 obtained using the **fixed-effects** model
 308 described above. SNP-level and gene-level
 309 summary statistics were reported in the main
 310 text. SNP-level summary statistics were
 311 aggregated into pathway-level p-values using
 312 *PascalX*. Benjamini-Hochberg (BH)
 313 procedure on significant pathways from the
 314 discovery cohort doesn't replicate any hits in
 315 the replication meta-cohort (SKIPOGH +
 316 OphthalmoLaus)

301



317

318

319

320

321

322

323

317 **Supplemental Figure 9 | Replication meta-analysis with random-effects.** Meta-GWAS

318 summary statistics were obtained using the **random-effects** meta-analysis tool RE2C. Left:

319 Benjamini-Hochberg (BH) procedure on lead SNPs discovered in the UK Biobank yields 4 hits in

320 the replication cohort. Center and Right: No discovered genes and pathways replicate in the meta-

321 cohort. SNP-wise p-values were aggregated into gene and pathway scores using *PascalX*.

322

323

324 SUPPLEMENTAL RESULTS


325 Text 6: Baseline Characteristics

326 Across the analyzed individuals, mean±SD age = 56±8 years; 35 098 females at birth (54%); 4 618
327 smokers (7%), mean±SD BMI = 27±5 kg/m², mean±SD SBP = 140±20 mmHg, mean±SD DBP =
328 82±11 mmHg. 54 343 (94%) self-reported ethnicity as White, 1 243 (2.1%) as Asian, 962 (1.7%) as
329 Black, 373 (0.6%) as Mixed, 175 (0.3%) as Chinese, and 521 (0.9%) as Other.

330 Among the participants for which at least one retinal fundus image was available, 2 644 had been
331 diagnosed with type 2 diabetes, 1 448 with angina, 1 077 with myocardial infarction, 1 072 with deep-
332 vein thrombosis (i.e., blood clot in the leg), 750 with stroke, 8 797 lived with stage 2 hypertension
333 (i.e., automated reading of blood pressure >90 mmHg diastolic or >140 mmHg systolic); among the
334 participants for which at least one fundus image was available, 2 644 had been diagnosed with type
335 2 diabetes, 1 448 with angina, 1 077 with myocardial infarction, 1 072 with deep-vein thrombosis (i.e.,
336 blood clot in the leg), 750 with stroke, 8 797 lived with stage 2 hypertension (i.e., automated reading
337 of blood pressure >90 mmHg diastolic or >140 mmHg systolic).

338 Text 7: Correlation with disease status

339 We built a logistic regression classifier and found retinal vein tortuosity to have predictive power over
340 disease outcome: angina AUC 55.2%, heart attack AUC 53.4%, stroke AUC 54.6%, Deep Vein
341 Thrombosis (DVT) AUC 53.3% and hypertension AUC 56.6%. To determine whether retinal
342 tortuosity might be used as an independent biomarker for CVD, we trained logistic regression models
343 with known risk factors: age, sex, SBP and smoking (pack years): angina AUC 76.2%, heart attack
344 AUC 80.6%, stroke AUC 69.3%, DVT 61.8%, The same procedure was applied to the prediction of
345 hypertension, but without using SBP as a risk factor, resulting in AUC 75.4%. These risk factors
346 models did not significantly increase in performance by adding any of the median vessel tortuosity
347 measures: we conclude that, despite associations with CVD outcome, retinal tortuosity does not
348 represent an increased health risk after correcting for known risk factors. The analysis was
349 performed on all vessels, then repeated only on veins and only on arteries. Results varied slightly.
350 To illustrate this, we show the distributions of median vessel tortuosity in hypertensive patients vs.
351 controls.



352 **Supplemental Figure 10 | Predictive power of median tortuosity over hypertension.** Effects
353 and p-values are calculated using linear regression. AUC refers to logistic regression.
354

355 **Text 8: Replication of known hits**

356 We replicated two known associations. We failed to replicate a third, for which association was
 357 controversial (it was only marginally significant in its discovery cohort and had failed replication in
 358 the independent cohort of the study that originally proposed it).


359

RSID	REPLICATED in our GWAS	REPLICATED in its own study	POSITION	GENE(S)	trait
rs1808382	yes	yes	19: 38.7 Kb	ACTN4 / CAPN12	retinal venular tortuosity
rs7991229	yes	yes	13: 111.1 Kb	COL4A2	retinal arteriolar tortuosity
rs73157566	no	no	12: 129.5 Kb	NLRP9P1	retinal venular tortuosity


360 **Supplemental Table 2 | Known associations with retinal vessel tortuosity.** Three SNPs known
 361 to associate with a phenotype related to retinal vessel tortuosity in the literature[4]. Details can be
 362 found in the list of all statistically significant SNPs (see Supplemental Dataset 1A/1B/1C).

363


364



365 **Supplemental Figure 11 | LocusZoom of known associations with rs1808382.** Although we
 366 did not recover the exact rsid variant, we report a number of exonic variants (more likely to be
 367 causative) in extremely strong LD, which represent our strongest signal: in particular, we recovered
 368 a variant in perfect LD, rs16972767, which is an intron variant for ACTN4, the gene on which
 369 rs1808382 was reported as having potential direct regulatory effects[4]. rs16972767 is reported in
 370 the literature as a venular tortuosity hit: in accordance with this, its significance was higher in our
 371 venular tortuosity GWAS ($-\log_{10} p=165$) rather than in our arteriolar tortuosity GWAS ($-\log_{10} p=65$).
 372




373
 374 **Supplemental Figure 12 | LocusZoom of known associations with rs7991229.** This SNP was
 375 reported in the literature as an association to arteriolar tortuosity: indeed, its significance was
 376 substantially higher in our artery tortuosity GWAS ($-\log_{10} p=166$) than in our vein tortuosity GWAS
 377 ($-\log_{10} p=8$).




378
 379 **Supplemental Figure 13 | LocusZoom of (controversial) known associations with**
 380 **rs73157566.** We did not reproduce it. Given the fact that this association had not reached
 381 genome-wide significance in its own replication cohort, we propose this locus should not be
 382 considered as associated retinal vessel tortuosity.

383 **Text 9: Vessel-type comparisons for SNPs, Genes and Pathways**


384
385 **1) SNPs**



386
387
388
389 **2) Genes**



390
391
392
393
394 **3) Pathways**



395
396
397 **Supplemental Figure 14 | Venn diagrams.** Overlap between Bonferroni-thresholded 1) SNPs, 2)
398 genes and 3) pathways across phenotypes. Left: **Hits exclusive to artery GWAS vs. vein**
399 **GWAS:** Venn diagram showing overlap between significant 1) SNPs, 2) genes, 3) pathways in
400 arteries and veins. We find overall more significant SNPs, genes and pathways in arteries, and
401 also more than twice as many artery-exclusive SNPs, genes and pathways than vein-exclusive.
402 Right: **Hits exclusive to artery GWAS vs. vein GWAS vs. all-vessels (combined-vessel-type**
403 **GWAS):** Combining arteries and veins into a single “all vessels” phenotype catches many of the
404 SNPs, genes and pathways detected by the artery and vein phenotypes and also provide some
405 news.

406 **Text 10: Genetic associations with disease and risk**

407 **Tortuosity variants associated with disease outcome**

SHARED SNP	ref	DISEASE GWAS
rs3184504	[5]	Coronary heart disease
rs2472299	[6]	
rs10483727	[7]	Glaucoma
rs3184504	[8]	
rs35155027	[8]	
rs10483727	[7]	
rs34935520	[7]	
rs10774625	[9]	Hypertension
rs6495127	[9]	
rs3184504	[10]	Type 1 diabetes
rs3184504	[11]	
rs653178	[12]	Chronic kidney disease
rs653178	[13]	Celiac disease
rs4766578	[12]	Heart failure
rs4766578	[14]	Vitiligo
rs1129038	[14]	
rs653178	[12]	Chronic kidney disease

408 **Supplemental Table 3 | Variants associated with disease.** List of variants influencing both
 409 tortuosity and disease outcome without statistically significant association to a gene.

SHARED SNP	ref	DISEASE GWAS
rs78058190	[15]	Cardiovascular diseases
rs10942863	[15]	
rs62434109	[15]	
rs3184504	[15]	
rs11072508	[15]	
rs189349094	[15]	
rs72938315	[15]	
rs72938315	[15]	Respiratory diseases
rs7687906	[16]	Obesity-related traits
rs3184504	[10]	Autoimmune traits
rs7310615	[15]	

410 **Supplemental Table 4 | Variants associated with disease (general outcome).** List of variants
 411 influencing both tortuosity and general non-specific disease outcomes (e.g., "Obesity-related traits"
 412 does not specify the exact disease outcome).

413 **Tortuosity variants associated with disease risk factors**

SHARED SNP	ref	RISK FACTOR
rs35155027	[8]	Intraocular pressure (open-angle glaucoma)
rs8053277	[8]	Vertical cup-disc ratio (glaucoma)
rs3184504	[17]	Systolic blood pressure (CVD)
rs1378942	[18]	
rs3184504	[17]	Diastolic blood pressure (CVD)
rs3184504	[18]	
rs653178	[19]	
rs653178	[20]	Mean arterial pressure (CVD)
rs597808	[15]	Waist-hip ratio (obesity)
rs78058190	[15]	
rs4744056	[21]	General cognitive ability (mental disorders)

414 **Supplemental Table 5 | Variants associated with risk of disease.** List of variants influencing
 415 both tortuosity and disease outcome without statistically significant association to a gene.


416

Text 11: Mendelian Randomization


Tortuosity -> Outcome					Exposure -> Tortuosity				
Exposure	Outcome	Effect	SE	Pvalue	Exposure	Outcome	Effect	SE	Pvalue
artery	BMI	0.019	0.015	0.200	BMI	artery	0.028	0.030	0.356
mixed		0.008	0.015	0.581		mixed	-0.011	0.029	0.715
vein		-0.044	0.018	0.013		vein	-0.047	0.027	0.078
artery	CAD	-0.053	0.041	0.200	CAD	artery	-0.018	0.028	0.524
mixed		-0.061	0.038	0.109		mixed	-0.008	0.024	0.748
vein		-0.076	0.046	0.097		vein	-0.002	0.016	0.924
artery	SBP	-0.200	0.362	0.581	SBP	artery	-0.017	0.017	0.324
mixed		0.033	0.344	0.924		mixed	-0.015	0.015	0.309
vein		-0.035	0.538	0.948		vein	-0.010	0.009	0.252
artery	HDL	0.017	0.015	0.236	HDL	artery	0.010	0.008	0.235
mixed		0.014	0.015	0.351		mixed	0.011	0.009	0.193
vein		0.009	0.024	0.722		vein	0.008	0.009	0.383
artery	LDL	-0.001	0.016	0.940	LDL	artery	-0.046	0.013	0.001
mixed		0.006	0.017	0.709		mixed	-0.043	0.013	0.001
vein		0.002	0.029	0.945		vein	-0.031	0.013	0.018
artery	TC	0.000	0.017	0.991	TC	artery	0.000	0.002	0.947
mixed		0.006	0.019	0.741		mixed	0.000	0.002	0.960
vein		-0.006	0.032	0.844		vein	0.000	0.002	0.963
artery	TG	-0.006	0.013	0.656	TG	artery	-0.038	0.018	0.038
mixed		0.003	0.013	0.833		mixed	-0.034	0.016	0.038
vein		-0.008	0.022	0.720		vein	-0.014	0.014	0.301

417 **Supplemental Table 6 | Bi-directional Mendelian Randomization results.** Causal estimates are
 418 based on the inverse variance weighted (IVW) method. Abbreviations: Body Mass Index (BMI),
 419 Coronary artery disease (CAD), Systolic Blood Pressure (SBP), High-density lipoprotein (HDL),
 420 Low-density lipoprotein (LDL), total cholesterol (TC) and triglycerides (TG). No multiple hypothesis
 421 correction was applied.

422 **Text 12: ACTN4 and COL4A2 over-expression**



423



424

425


426

427

428

Supplemental Figure 15 | ACTN4 and COL4A2 abundance according to GTEx. The two highly significant genes' ACTN4 and COL4A2 mRNAs were both found to be highly abundant in blood vessels.


429 **Text 13: Full gen set enrichment results**



430


431 **Supplemental Figure 16 | Extended version of Figure 5 from the main text (GO terms).**

432 Extended version where all enriched GO terms are shown (irrespective of them being very general
 433 or redundant) . Additionally, label names are printed out in full. The number of genes in each set is
 434 indicated in squared brackets.



437 **Supplemental Figure 17 | Extended version of Figure 5 from the main text (pathways).**

438 Extended version where all enriched pathways are shown (irrespective of them being very general
 439 or redundant) . Additionally, label names are printed out in full. The number of genes in each set is
 440 indicated in squared brackets.



443 **Supplemental Figure 18 | Extended**
 444 **version of Figure 4 from the main text.**
 445 Extended version where all traits with at least
 446 3 shared associations are included. For full
 447 data, refer to Supplemental Dataset 3.

441
448

449 **List of label replacements**

450 Supplemental Figure 18 was generated based on data in Supplemental Dataset 3. The following
451 replacements were applied to the column "Trait" to homogenize or shorten some labels.

452 "Blood pressure"<-"Blood/pulse pressure"
453 "Pulse pressure"<-"Blood/pulse pressure"
454 "Systolic blood pressure"<-"Blood Pressure (SBP)"
455 "Mean arterial pressure"<-"Blood Pressure (SBP)"
456 "Diastolic blood pressure"<-"Blood Pressure (DBP)"
457 "Blood pressure traits (multi-trait analysis)"<-"Blood Pressure (DBP)"
458 "Body mass index"<-"BMI and body fat"
459 "Body fat percentage"<-"BMI and body fat"
460 "Fat-free mass"<-"BMI and body fat"
461 "Body mass index (joint analysis main effects and physical activity interaction)"<-"BMI and body fat"
462 "BMI and body fat (joint analysis main effects and physical activity interaction)"<-"BMI and body fat"
463 "Waist-to-hip ratio adjusted for BMI (additive genetic model)"<-"BMI and body fat"
464 "Waist-hip ratio"<-"BMI and body fat"
465 "Hip circumference adjusted for BMI"<-"BMI and body fat"
466 "Obesity-related traits"<-"BMI and body fat"
467 "Triglycerides"<-"Cholesterol levels"
468 "Cholesterol, total"<-"Cholesterol levels"
469 "LDL cholesterol"<-"Cholesterol levels"
470 "High density lipoprotein cholesterol levels"<-"Cholesterol levels"
471 "Low density lipoprotein cholesterol levels"<-"Cholesterol levels"
472 "Total cholesterol levels"<-"Cholesterol levels"
473 "HDL cholesterol"<-"Cholesterol levels"
474 "C-reactive protein levels or LDL-cholesterol levels (pleiotropy)"<-"Cholesterol levels"
475 "Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass
476 grafting, angina or chronic ischemic heart disease)"<-"CVD"
477 "Myocardial infarction (early onset)"<-"CVD"
478 "Coronary artery disease or ischemic stroke"<-"CVD"
479 "Coronary artery disease or large artery stroke"<-"CVD"
480 "Cardiovascular disease"<-"CVD"
481 "Ischemic stroke"<-"CVD"
482 "Stroke"<-"CVD"
483 "Stroke (large artery atherosclerosis)"<-"CVD"
484 "Stroke (small-vessel)"<-"CVD"
485 "Myocardial infarction"<-"CVD"
486 "Ischemic stroke (small-vessel)"<-"CVD"
487 "Coronary artery disease"<-"CVD"
488 "Coronary heart disease"<-"CVD"
489 "CVD (small-vessel)"<-"CVD"
490 "Type 1 diabetes"<-"Diabetes (T1)"
491 "Latent autoimmune diabetes vs. type 2 diabetes"<-"Diabetes (T1)"
492 "Latent autoimmune diabetes vs. type 2 diabetes"<-"Diabetes (T2)"
493 "Type 2 diabetes"<-"Diabetes (T2)"
494 "Intraocular pressure"<-"Eye morphology traits"
495 "Macular thickness"<-"Eye morphology traits"
496 "Vertical cup-disc ratio"<-"Eye morphology traits"
497 "Optic cup area"<-"Eye morphology traits"
498 "Optic disc area"<-"Eye morphology traits"
499 "Eye color traits"<-"Eye morphology traits"
500 "Eye color"<-"Eye morphology traits"
501 "Eye color (brightness)"<-"Eye morphology traits"
502 "Eye color (hue)"<-"Eye morphology traits"
503 "Retinal vascular caliber"<-"Eye morphology traits"
504 "Eye color (saturation)"<-"Eye morphology traits"
505 "Blue vs. green eyes"<-"Eye morphology traits"
506 "Blue vs. brown eyes"<-"Eye morphology traits"
507 "Optic disc parameters"<-"Eye morphology traits"
508 "Optic disc parameters"<-"Hair morphology traits"
509 "Hair color"<-"Hair morphology traits"
510 "Hair morphology traits"<-"Hair morphology traits"
511 "Blond vs. brown/black hair color"<-"Hair morphology traits"
512 "Black vs. blond hair color"<-"Hair morphology traits"
513 "Black vs. red hair color"<-"Hair morphology traits"
514 "Blond vs. brown hair color"<-"Hair morphology traits"
515 "Brown vs. black hair color"<-"Hair morphology traits"
516 "Red vs. brown/black hair color"<-"Hair morphology traits"
517 "Skin pigmentation traits"<-"Skin morphology traits"
518 "Skin pigmentation"<-"Skin morphology traits"
519 "Perceived skin darkness"<-"Skin morphology traits"

520 "Glaucoma (primary open-angle)"<-"Glaucoma"
521 "Glaucoma (high intraocular pressure)"<-"Glaucoma"
522 "Lung function (FEV1/FVC)"<-"Lung function"
523 "Lung function (FEV1)"<-"Lung function"
524 "Post bronchodilator FEV1/FVC ratio"<-"Lung function"
525 "FEV1"<-"Lung function"
526 "Peak expiratory flow"<-"Lung function"
527 "Lung function (FVC)"<-"Lung function"
528 "Lung function (Lung function)"<-"Lung function"
529 "Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)"<-"SBP x alcohol/smoking"
530 "Mean arterial pressure x alcohol consumption interaction (2df test)"<-"SBP x alcohol/smoking"
531 "Blood Pressure (SBP) x alcohol consumption interaction (2df test)"<-"SBP x alcohol/smoking"
532 "Systolic blood pressure (alcohol consumption interaction)"<-"SBP x alcohol/smoking"
533 "Blood Pressure (DBP) x alcohol consumption interaction (2df test)"<-"DBP x alcohol/smoking"
534 "Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)"<-"DBP x alcohol/smoking"
535 "Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)"<-"DBP x alcohol/smoking"
536 "Blood Pressure (SBP) x alcohol consumption (light vs heavy) interaction (2df test)"<-"SBP x alcohol/smoking"
537 "Blood Pressure (DBP) x alcohol consumption (light vs heavy) interaction (2df test)"<-"DBP x alcohol/smoking"
538 "Blood Pressure (SBP) (cigarette smoking interaction)"<-"SBP x alcohol/smoking"
539 "Blood Pressure (DBP) (cigarette smoking interaction)"<-"DBP x alcohol/smoking"
540 "Systolic blood pressure x alcohol consumption interaction (2df test)"<-"SBP x alcohol/smoking"
541 "Diastolic blood pressure x alcohol consumption interaction (2df test)"<-"DBP x alcohol/smoking"
542 "Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)"<-"SBP x alcohol/smoking"
543 "Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)"<-"DBP x alcohol/smoking"
544 "Systolic blood pressure (cigarette smoking interaction)"<-"SBP x alcohol/smoking"
545 "Diastolic blood pressure (cigarette smoking interaction)"<-"DBP x alcohol/smoking"
546 "Educational attainment (MTAG)"<-"Educational attainment"
547 "Highest math class taken (MTAG)"<-"Educational attainment"
548 "Cognitive performance (MTAG)"<-"Cognitive performance"
549 "Parental longevity (combined parental attained age, Martingale residuals)"<-"Parental longevity"
550 "Educational attainment (years of education)"<-"Educational attainment"
551 "Alcohol consumption (drinks per week)"<-"Alcohol (drinks/week)"
552 "Mean corpuscular hemoglobin"<-"Hemoglobin (MCHC)"
553 "Mean corpuscular hemoglobin concentration"<-"Hemoglobin (MCHC)"
554 "Systemic lupus erythematosus"<-"Lupus (SLE)"
555 "Morning vs. evening chronotype"<-"Morning person"
556 "Chronotype"<-"Morning person"
557 "Primary sclerosing cholangitis"<-"Sclerosing (PSC)"
558 "Urinary metabolites (H-NMR features)"<-"Urinary metabolites"
559 "Heel bone mineral density"<-"Bone mineral density"
560 "Chronic lymphocytic leukemia"<-"Leukemia (CLL)"
561 "Dietary macronutrient intake"<-"Macronutrient intake"
562 "Eosinophil percentage of granulocytes"<-"Eosinophil vs granulocytes"
563 "Eosinophil percentage of white cells"<-"Eosinophil vs white cells"
564 "Neutrophil percentage of granulocytes"<-"Neutrophil vs granulocytes"
565 "Sum eosinophil basophil counts"<-"Eosinophil + basophil"
566 "White matter hyperintensity burden"<-"Hyperintensity (WMH)"
567 "Inflammatory bowel disease"<-"Bowel disease (IBD)"